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ABSTRACT
The nature and uses o f some steroidal hormones and anti-hormones 
are reviewed, with an emphasis on the anti-progestins which have 
anti-implantation activity. A  new type o f steroid structure has been 
designed which combines two types o f structural elements, namely 
an A-nor skeleton and an 11-aryl substituent, which are separately 
known to display anti-implantation properties.
It is demonstrated that a thallium-mediated ring contraction o f 
steroidal 4-en-3-ones carrying an 11-keto group provides entry to a 
functionalised A-nor steroid skeleton which can then be arylated 
using organolithium reagents. Manipulation o f the functionalities led 
to the successful synthesis o f ll-phenyl-A-nor-5ft-androst-2,17- 
dione, which should be a valuable intermediate for the generation of 
a set o f 11-arylated A-nor steroids for biological evaluation.
m
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CHAPTER 1
Introduction - Hormones and Anti-hormones 
1.1 The Endocrine Hormones
The endocrine system consists o f a number o f ductless glands that 
produce highly active chemical regulators called hormones. These 
chemical messengers are secreted in the bloodstream and carried to 
certain target organs where they act upon specific receptor cells**
Hormones regulate metabolism and assist in the perpetuation o f the 
species by influencing a wide variety o f biological systems to perform 
several functions;
a) To maintain a constant internal environment in the body fluids 
i.e. homeostasis
b) To regulate the general growth and development o f the body
c) To aid sexual maturation, to maintain sexual rhythms, and to 
facilitate the reproductive process.
d) To regulate energy production and to stabilize the metabolic 
rate.
e) To help the body adjust to stressful or emergency situations.
There are three main functional types o f hormones. The first o f these 
are the releasing factors from the hypothalamus, which stimulate the 
secretion o f some anterior pituitary hormones. Releasing factors act 
only upon the anterior pituitary. The second functional type o f 
hormone is known as a tropic hormone. These are produced by the 
pituitary gland and stimulate the growth and activity o f specific
l
endocrine glands^. They include thyrotropin TSH, a hormone that 
causes the thyroid gland to produce thyroxine, adrencorticotropin 
ACTH, which stimulates the adrenal cortex to produce cortisol, and 
the gonadotropins, FSH and LH, which stimulate the ovaries to 
produce estrogen and the testes to produce testosterone, respectively. 
The other main functional type are the effector or nontropic 
hormones which are mainly produced by the endocrine glands and 
exert their metabolic effects upon nonendocrine tissues. Gonadal 
hormones affect a wide variety o f tissues during puberty to produce 
the typical secondary sex characteristics for each sex; thyroid 
hormones affect the metabolic rates o f all tissues, growth hormone 
stimulates skeletal growth and affects many metabolic processes.
1.2 Chemical Types
There are five general chemical types o f hormones; glycoproteins, 
proteins or long-chain polypeptides, short-chain polypeptides, amino 
acid derivatives and steroids. The anterior pitutary hormones TSH, 
FSH and LH are either glycoproteins or long-chain polypeptides, and 
the posterior pituitary hormones ADH and all o f the hypothalamus 
releasing factors are short-chain peptides. Hormones from  the 
adrenal cortex and the gonads are steroids, whilst epinephrine and 
norepinephrine from the adrenal medulla are amines derived from 
the amino acid tyrosine^.
The production and secretion o f hormones by an endocrine gland may 
be initiated by one or more o f several different types o f signals: for 
example, by the stimulation o f the cerebral cortex by thoughts, 
emotions, stress and by chemical transmitters active at nerve
2
junctions. It may also be caused by a variation in blood osmolality or 
volume e.g. secretion o f antidiuretic hormone, ADH, by the posterior 
pituitary when the plasma osmolality increases and secretion o f renin 
by the kidney in response to low blood volume. It can also be 
initiated by the release o f hormones in the gastrointestinal tract in 
the presence o f various foods.
1.3 Hypothalamic Regulation
The control and regulation of the hormones that exert such profound 
effects on so many tissue cells are very complicated. Figure (1.1) is a 
schematic representation of reproducive hormonal control, where the 
primary control is believed to rest in the hypothalamus, which is a 
small gland and nerve centre situated above the pituitary.
The isolation, characterisation and synthesis o f hormone-releasing 
factors have firm ly established their role in the physiology o f 
endocrine secretion. Some o f these peptides (TRH, thyroid-releasing 
hormone and GnRH, gonadotropin releasing hormone) release more 
than one hormone and others inhibit release (PIF, peptide inhibit 
factor, somatostatin). In addition, these peptide hormones influence 
behaviour and affect neuronal excitability within the hypothalamus4.
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Thyroid-stimulating hormone (TSH) is the primary regulator o f the 
thyroid gland, and it is secreted in response to TRH. TRH stimulates 
thyrotrophs and lactotrophs to release TSH and prolactin respectively, 
through an adenylate cyclase-dependent mechanism. Thyroid 
hormone inhibits this effect at the thyrotropin-producing cell, but 
on ly  partia lly  decreases the effect on prolactin secretion. 
Somatostatin also blocks TRH-induced secretion o f TSH. In some types 
o f pituitary abnormalities, such as in acromegaly or in certain 
tumours, TRH also stimulates release o f growth hormone.
Corticotropin releasing factor (CRF) is a potent hypothalamic regulator 
o f ACTH formation and release. CRF has been identified in multiple 
sites in the central nervous system and also in peripheral tissues and 
some tumours. It is used clinically to test for abnormalities o f the 
hypothalamic-pituitary-adrenal axis. Patients with Cushings disease 
exhibit a normal or exaggerated release o f ACTH in response to 
exogenous CRF, in contrast to those with ectopic ACTH secretion who 
fail to respond. CRF is also used to evaluate ACTH release in 
depressed people and in patients with anorexia nervosa^.
GnRH is the gonadotropin releasing hormone, also known as 
luteinising hormone-releasing hormone LHRH. It is a decapeptide that 
is responsible fo r regulating the secretion o f the pituitary 
gonadotropins FSH and LH.
GnRH is used to treat hypothalamic amenorrhea, isolated 
gonadotropin deficiency and carcinoma o f the prostate. Intermittent
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administration o f the hormone causes sustained secretion o f both FSH 
and LH and administration o f GnRH to men with primary GnRH 
deficiency has been proved to result in growth o f the testes and a 
gradual increase in sperm count.
GnRH antagonists act as competitive inhibitors at GnRH receptors. 
Through blockade o f the actions o f endogenous GnRH, they also 
suppress secretion o f gonadal steroids. In contrast to the effect o f 
GnRH agonists, the hypogonadal state is produced without initial 
pituitary stimulation.
The growth hormone-releasing hormone (GHRH) along with 
somatostatin, directly controls the synthesis and release o f growth 
hormone from pituitary somatotrophs. Although it has only fairly 
recently been recognised, GHRH is a very useful agent in the diagnosis 
and treatment o f growth hormone deficiency.
Because hypothalamic lesions decrease GH production and retard 
growth, research on control o f GH secretion by GRF has led to isolation 
and purification o f somatostatin, a tetradecapeptide that inhibits GH 
release. This peptide has an extensive distribution within the 
nervous system and in many peripheral tissues, including the 
gastrointestinal tract and endocrine and exocrine glands. Like many 
other regulatory factors, somatostatin is synthesised in a longer form 
that is also active.
Somatostatin is a potent suppresser o f GH release and it blocks the GH 
response to exercise, insulin-induced hypoglycohemia and levodopa
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injection. Neurotransmitters and neuropeptides that m odify 
somatostatin release also affect GH concentration.
Somatostatin is also found in many cells that have nothing to do with 
GH, and it inhibits secretion o f several other pituitaiy and peripheral 
hormones, such as TSH, prolactin, ACTH, glucagon, insulin, and gastrin. 
Inhibition o f hormone secretion and also secretion o f peptides from 
cancer cells may depend on a common mechanism such as interaction 
with a guanine nucleotide regulatory protein that inhibits adenylate 
cyclase. Also somatostatin is believed to be involved in virtually all 
sensory systems.
Growth hormone (GH), is the most abundant hormone o f the anterior 
pituitary, and it has important effects on the metabolism. By 
decreasing glucose utilisation, antagonising insulin, increasing amino 
acid transport and protein synthesis, GH promotes protein synthesis 
at the expense o f carbohydrate and fat.
A  deficiency o f GH in children causes dwarfism and an excess causes 
giantism. A  hypersecretion of GH occurring in adulthood after closure 
o f the long bones results in large, gross-featured persons, a condition 
known as acromegaly.
1.4 Female sex hormones
The reproductive system in females is more complex than that in 
males. This is due to the cyclical events that take place during the 
menstrual cycle and the even greater changes that occur during a 
pregnancy. Two different chemical types o f steroid hormones are
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produced and secreted by the ovary in non-pregnant females. During 
pregnancy, the same hormones are produced by the ovary, but in 
different proportions.
The placenta also makes the hormones that are necessary fo r the 
maintenance o f pregnancy^.
One group o f female sex hormones are the estrogens which originate 
in the ovarian follicles. The estrogens participate in the menstrual 
cycle and are essential for the development and maintenance o f the 
reproductive organs and secondary sex characteristics. The second 
group consists o f progesterone and its metabolites, which are formed 
in the corpus luteum, the body that develops from the ruptured 
ovarian follicle.
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The ovarian cycle in the mature female reflects changes in 
gonadotropins, in steroid synthesis, and in the histology o f the ovaries 
and endometrium. The underlying mechanism that coordinates these 
events is the acquisition o f specific hormone receptors that enable 
cells to respond to the circulating hormones. The hormonal control of 
menstruation is illustrated in Fig ( 1.2 ).
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The actual measurements o f serum hormone concentrations are 
shown in Fig(1.3). These concentrations o f progesterone are plotted 
against mean concentrations o f FSH and LH determined in normal 
women and centred according to the day of LH peak i.e. day 0.
Fig. 1.3
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In the female, estrogens such as estradiol stimulate the thickening 
and vascularization o f the lining o f the uterus (endometrium), 
preparing it for implantation. After ovulation at the mid-point o f the 
monthly cycle, the ovum released from its burst follicle on the 
ovarian surface travels down the fallopian tube towards the uterus. 
In the course o f its fallopian transport, the ovum may meet 
spermatozoa and fuse with one o f them in the process o f fertilization. 
Following this, a fertilized ovum will begin to grow and the resulting 
group o f cells (blastocyst) may then become attached to the uterine 
wall and develop into an embryo and later into a foetus. This is 
interfaced with the maternal blood system through the placenta that 
develops during the early stages o f pregnancy^.
A fter the release o f the ripened ovum at the mid-point in the 
monthly cycle, the burst follicular sack is transformed into a solid 
secretory body known as the corpus luteum. Under the controlling 
influence o f pituitary LH, the corpus luteum secretes progesterone, 
which maintains the receptivity o f the uterine endometrium to 
implantation and also is essential to maintain the implantation as 
pregnancy develops. During pregnancy, progesterone also performs 
several other vital hormonal functions, including stimulation o f the 
development o f mammary tissue for later lactation and inhibition o f 
the release o f any further ova. The high level o f progesterone is so 
important during pregnancy that, in addition to its continued 
secretion by the corpus luteum, it also begins to be made in large 
quantities by the placenta as the pregnancy progresses.
As the blastocyst implants and begins its development, it emits a 
signalling substance known as human chorionic gonadotropin (HCG).
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This is a glycoprotein hormone that resembles pituitary LH in that 
they have identical<Kchains but different & chains; they have similar 
hormonal action in stimulating the corpus luteum to produce 
progesterone, which helps to maintain the pregnancy.
The formation o f HCG by the chorion o f the developing placenta 
begins shortly after implantation o f the fertilized egg in the uterine 
wall. Its concentration in plasma and urine rises steadily from the 
first week after conception for the next 10 to 12 weeks. It was the 
recognition o f the early presence o f HCG in urine that became the 
basis for some pregnancy testing kits.
1.5 Estrogens
The principal and most potent estrogen is estradiol-17£ (4),which is 
partially converted in the body to estrone (3 ), a much weaker 
hormone. Estriol, a metabolite o f estrone, also has some estrogenic 
activity. A ll three o f these estrogens are excreted in urine as 
glucuronides and sulphates**.
Biosynthetically, estrogens are formed from  the androgenic 
precursors androstened ione ( 1) and testosterone ( 2 ). 
Androstenedione is converted by the ovary to testosterone, which is 
then aromatised and demethylated to estrogens. Aromatisation o f the 
A  ring o f the steroid is required for estrogenic activity. I f  this 
reaction is defective, circulating androgenic precursors can cause 
virilization Fig (1.4).
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Estrogens are the female sex hormones and are basically responsible 
for the development and maintenance o f accessory sex organs and 
secondary sexual characteristics in the female. They induce 
proliferation in the epithelium of the fallopian tubes, endometrium, 
cervix and vagina. Especially in the preovulatory phase, estrogens 
produce changes in the tubular mucosa and stimulate the contraction 
and motility o f the fallopian tubes, which promote the transport o f 
the ovum. The growth o f the endometrial mucosa is accompanied by 
an increased blood supply to this tissue produced by increased coiling 
o f the spiral arterioles.
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Estrogens, along with pituitary factors and progesterone, stimulate 
mammary growth. While the proliferation o f the lobular-alveolar 
system in primates is under progesterone control, estrogens are 
responsible fo r the growth o f the stroma and duct system. The 
growth and pigmentation of the nipples as well as o f the labia o f the 
vagina are stimulated by estrogens. In women, the distribution of 
subcutaneous fat and of body hair and the smooth character o f the 
skin are likewise controlled by estrogens. Estrogens induce the 
opening o f the vaginal introitus in rodents, and estriol has been 
shown to increase the size o f the vagina in rabbits. It is likely that 
this hormone increases the lumen o f the birth canal in preparation 
for delivery^.
Estrogen secretion is under the control o f pituitary gonadotropins. 
Conversely, large doses o f estrogens may act on the hypothalamus to 
inhibit the release o f the follicle-stimulating and luteinising hormones 
and may therefore inhibit ovulation and eventually lead to involution 
o f accessory sex organs. During pregnancy, the estrogens act with 
progesterone to aid nidation, maintain gestation, block the production 
o f lactogenic hormone and finally facilitate parturition. Excessive 
doses o f hormone may depress growth hormone production and lead 
to stunted growth and premature closure o f the epiphyses. The rise 
in body temperature at ovulation may be due to an effect o f 
estrogens on the basal metabolic rate. Estrogens also have some 
effect on salt and water retention and may raise the blood pressure. 
They decrease clotting time and are also clinically useful in the 
control o f bleeding.
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Folic acid is necessary for the response o f the genital tract to 
estrogens. The androgenic adrenocortical and progestational 
hormones antagonise some o f the effects o f estrogens. Estrone and 
estradiol inhibit the effect o f testosterone on comb growth in the 
capon. Estrogens have been linked in the past with tumours in 
certain animals, but in other cases they have had the opposite effect 
in that estrogen treatment has benifited some patients with cancer o f 
the breast or prostate. Estrogen treatment is also used in female 
hypogenitalism, in certain cases o f menstrual dysfunctions, for 
menopausal symptoms, for engorged breasts, in senile vaginitis and 
in pruritus vulvae. The toxic side effects, such as nausea and 
vomiting, are similar to those sometimes observed in pregnancy. In 
primates, withdrawal o f estrogen treatment produces bleeding 
similar to menstruation.
1.6 Estrogen receptors
The actions o f estrogens on target tissues are mediated through 
specific tissue receptors. High concentrations o f estrogen-binding 
protein are found in the uterus, vagina and mammary glands, but 
estrogens are also found in many other tissues. These receptors, like 
those for androgens and glococorticoids, belong to a superfamily o f 
proteins, all o f which are regulators o f gene transcription. Fig (1.5) 
shows how the steroids from the circulation diffuse into the cells, but 
only target cells have the appropriate receptors to retain them*®.
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The steroid hormone binds to the receptor and activates a change 
that allows the complex to bind to nuclear chromatin. Binding o f the 
steroid receptor complex to a specific nuclear acceptor site alters gene 
transcription.
1.6.1 Therapeutic uses
The main use o f estrogens is in combination with progestins in oral 
contraceptive preparations. The constant concentrations o f 
circulating hormones suppress secretion o f FSH and LH and also the
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midcycle surge o f LH just before ovulation. Therefore, follicle 
maturation is retarded and the stimulus for ovulation is suppressed.
Estrogens are used as replacement therapy in ovarian failure or at 
menopause to prevent osteoporosis and to relieve the symptoms o f 
estrogen deficiency. When estrogen secretion decreases at 
menopause, estrogen-responsive target tissues can cause several 
symptoms such as vasomotor instability, drying o f the vaginal 
mucosa, insomnia, irritability and other mood changes. As ovarian 
function declines with age, androstenedione from the adrenal cortex 
becomes the primary source o f estrogen, in the form  o f estrone. 
Because the naturally occurring concentration of androstenedione and 
the efficiency o f its conversion may vary considerably among 
individuals, estrogen replacement therapy is often used, in order to 
ease the transition into menopause.
Estrogens are also used to prevent or to treat osteoporosis, which is a 
reduction o f bone mass causing fragility or risk o f fracture, and they 
are equally effective in retarding bone loss in menopausal women, 
but up to now, studies have shown that they are only effective with 
continual administration.
Estrogens are used as androgen antagonists in certain androgen- 
sensitive cancers although the doses required are much higher than 
those needed for hormone replacement, and there is also a danger o f 
adverse effects.
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All compounds with estrogenic activity have virtually the same side 
effects and risks. Nausea is the most common side effect and others 
include fluid retention and breast tenderness. The severity o f the 
symptoms, which usually subside with continued use, is related to the 
potency o f the compound used. Recently there have been several 
studies which indicate an increase in the relative risk for endometrial 
or breast cancer in women who take estrogens as hormone 
replacement. Other serious risks o f estrogen therapy include an 
increased tendency toward thromboembolic disease, and there is also 
a small risk o f hypertension in a few people.
1.7 Progestins
The synthetic oral progestins are derivatives o f testosterone. If the 
19-methyl group o f testosterone is removed, its androgenic 
properties are significantly reduced and the product reveals 
progestational activity. Addition o f an acetylene group at the 17c< 
position also conveys progestational activity and produces compounds 
that are less rapidly metabolised by the liver. Fig (1.6) shows the 
chemical structures o f important progestins related to testosterone 
and 19-nortestosterone that are used as progestational agents4 . 
Arrows point where the basic norethindrone structure has been 
modified to produce new compounds.
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'T h e  effects o f progesterone are generally opposite to those o f 
estrogen. For example, it decreases myometrial contractions, 
increases glandular development o f the breast and endometrium and 
promotes secretion o f a viscous mucus from  cervical glands. 
However, like estrogens, it inhibits LH secretion through a negative 
feedback on the hypothalamic-anterior pituitary axis. There is more 
than one way by which the synthetic progestational hormones 
prevent conception. Firstly, alteration o f cervical mucus from  a 
watery, non-viscous secretion to a viscous, cellular secretion 
physically blocks sperm penetration. As well as this, progestational 
stimulation early in the ovarian cycle causes premature development 
o f endometrial glands and endometrial involution.
The main use o f progestins is in oral contraceptive formulations, and 
they are administered along with estrogens for treatment o f 
menopausal symptoms. In most oral contraceptive combinations, 
progestins are combined with a semisynthetic estrogen. Some 
compounds can be used alone, but oral contraceptives that contain 
only a progestin have a higher failure rate and may cause irregular 
bleeding. Progestins are also used to treat protracted uterine 
bleeding, dysmenorrhea, amonorrhea and endometriosis. The 
addition o f a progestin can help repair the necrotic endometrium, 
which allows natural shedding once the hormone is withdrawn.
There are several side effects associated with progestational agents, 
as indeed there are with any oral contraceptives and these are 
similar to symptoms associated with pregnancy. These effects 
include a gain in weight, depression and fatigue. These are probably
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due to its androgenic action, and in contrast to the nausea caused by 
estrogens, the symptoms do not usually subside with continued use.
Although it has often been thought in the past that there are certain 
links between long-term progestin use and cancer, there is no 
convincing evidence that this is the case and in fact, oral 
contraceptives actually appear to prevent some forms o f cancer. In a 
review  o f this issue*1, it has been suggested that blockade o f 
ovulation by pregnancy, lactation, or hormonal suppression may 
protect against endometrial and ovarian cancer. It also indicates 
however, that the case for cervical cancer is not so clear.
There are many compounds which have progestational activity. 
S em isyn th etic  d e r iv a t iv e s  o f  p ro g es te ro n e  in c lu d e  
medroxyprogesterone acetate and hydroxyprogesterone caproate. 
These have little estrogenic or androgenic activity and can be used by 
the injection method or in the case o f medroxyprogesterone acetate, 
also in tablet form.
The 19-norsteroids (6) have some estrogenic potency and this is 
probably because o f metabolism to estrogenic compounds. Some also 
have androgenic actions and the most commonly used agents are 
those included in oral contraceptives such as ethynodiol diacetate 
(12), norethindrone acetate(ll), norethynodrol(8),and norgestrol(lO).
1.8 Progesterone antagonists
It is necessary to keep up progesterone levels in order to maintain 
pregnancy and because o f this, antagonism o f progesterone receptors
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early in pregnancy can cause abortion. Mifepristone, also known as 
RU 486, is an antagonist at progesterone and glucocorticoid receptors, 
and is used to terminate early pregnancy. Another drug, epostane, 
terminates pregnancy through inhibition o f progesterone synthesis, 
blocking the conversion o f pregnenolone to progesterone by the 
enzyme 3-hydroxys teroid dehydrogenase.
1.9 Biosynthesis of steroids
One o f the main actions o f gonadotropins is to promote synthesis o f 
enzymes that catalyse various steps in the synthesis o f  steroid 
hormones. Androstenedione (1), which is the common precursor o f 
androgens and estrogens, is formed by the same mechanism in testis, 
ovary and adrenal cortex. The synthetic scheme is shown in Fig (1.7).
Acetate---------- ► Cholesterol------------ *~/\5 Pregnenolone
Progesterone 17 0<-OH-Pregnenolone
t
17 CK-OH-Progesterone Dehydroepiandrosterone
Androstenedione
Fig. 1.7
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1.10 Androgens
Androgens are the male sex hormones and the principal naturally 
occurring one is testosterone (2). This is formed in the Leydig cells 
under the influence o f LH. It is continuously secreted during adult 
life and is responsible for the development, function and maintenance 
o f the secondary male characteristics, the male accessory sex organs 
and for spermatogenesis. The androgens are also secreted from the 
adrenal cortex and the ovaries and they cause retention o f water, 
nitrogen, potassium, sodium, calcium, chloride, sulphate and 
phosphorus. They also increase protein anabolism1
Testosterone is converted in most parts o f the body to a more active 
metabolite, dihydrotestosterone (13). This acts at a cellular level like 
other steroid hormones by binding to a cytoplasmic receptor, which 
leads to the increased synthesis o f  RNA and protein . 
Dihydrotestosterone is more potent than testosterone and mediates 
most o f the androgenic effects attributed to testosterone1 Orally 
effective derivatives o f testosterone include methyltestosterone (14), 
fluoxymesterone (15) and methandrostenolone (16) Fig (1.8).
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1.10.1 Actions and uses of androgens
Testosterone has both androgenic and anabolic actions. The 
androgenic actions, as stated previously, are responsible for changes 
associated w ith sexual maturation and fo r  stim ulation o f 
spermatogenesis. In the early stages o f embryonic life, androgens 
prom ote development o f  the male phenotype. They are also 
responsible for the sudden growth at puberty and for the muscle 
mass in the maturing male. In addition to this, androgens stimulate 
growth and secretion o f sebaceous glands and growth o f facial hair14.
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The most important use o f androgens is replacement therapy when 
normal testosterone secretion is reduced or absent. They have been 
used in hypogonadism in the male and in some types o f infertility. 
Anabolic steroids are used in conditions in which there is a negative 
nitrogen balance such as in wasting diseases, malnutrition, severe 
anaemia or severe trauma, they also have a certain use in the 
treatment o f growth deficits or osteoporosis. Anabolic steroids are 
widely used by athletes in order to try to improve their strength and 
performance, or by bodybuilders who want to increase muscle 
weight. However, this can result in hepatic abnormalities, an 
elevated concentration o f LDL cholesterol or even coronary artery 
disease.
1.11 Male sex hormones
The hormonal control o f reproduction in the male is relatively simple 
compared to the female. The male gonads (testes) like the ovaries, 
have a double function; they produce and secrete the male hormone, 
testerone, and they also produce the spermatozoa which carry out the 
fertiliza tion  o f the ovum in the reproductive process. The 
spermatocytes gradually transform into round spermatids which 
eventually develop a tail, midpiece and compact head in the final 
spermatozoa. During these development stages, the sperm cells 
remain in close contact with Sertoli cells which line the inner walls o f 
the seminiferous tubules and maintain and nourish the growing 
sperm. A fter about ten weeks o f  developm ent w ithin the 
seminiferous tubules, the spermatozoa are released and are carried 
out o f the testes in a flow o f fluid, passing slowly through a very long, 
coiled duct called the epididymis. During their epididymal transport
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stage the spermatomoza undergo a number o f biochemical changes 
both in internal metabolism and, especially, in the nature o f the 
external surface coating, which leads to them acquiring motility and 
prepares them for the eventual process o f fusion with the ovum. On 
ejaculation, the contents o f the epididymis pass through a connecting 
tube and out through the urethra, acquiring additional fluids on the 
way which are contributed to the seminal fluid by ducts from  the 
prostate and Cowpers glands.
The Sertoli cells require two control agents to be present in order to 
function correctly, one being FSH from the pituitary gland and the 
other the androgenic steroid hormone, testosterone (2).
Production o f testosterone in the Leydig cells is under the control o f 
the pituitary hormone LH and, as in the female, the secretion o f both 
the gonadotrophins FSH and LH in the male pituitary is regulated by 
pulsatile signals o f Gn-RH from  the hypothalamus. Some 
testosterone is enzymatically reduced to 5<K-dihydrotestosterone in 
circulation, in peripheral tissues and in target tissues ( including cells 
in the testes and in accessory glands such as the prostate ) and it is 
the reduced form  o f the androgen which binds to the androgen 
receptor in many tissues. In addition to the primary function of 
maintaining spermatogenesis, androgens serve several other 
hormonal functions in the male. In particular, their continous 
presence in a sufficiently high plasma concentration is essential for 
the maintenance o f secondary sexual characteristics ( body 
musculature, hair, and voice) and libido and potency.
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1.12 Oral contraceptives
It was the recognition o f the key role o f progesterone (17) in 
inhibiting ovulation which led to the developm ent o f oral 
contraceptives in the mid-1950's. Progestational steroids act as 
antifertility compounds by suppression o f oestrus or prevention o f 
ovulation, via a feedback effect upon the secretion o f gonadotrophins 
by the anterior pituitary. There are many different types o f oral 
contraceptive and the most common o f these is a combination 
preparation which contains both progestin and estrogen. Single entity 
preparations are also available. A progestin alone has come to be 
known as the "minipill", while an estrogen alone is a postcoital or 
"morning after" pill. The minipills were introduced to eliminate the 
estrogen, which is the agent in combined preparations thought to be 
responsible fo r most o f the side effects o f  oral contraceptives. 
However, these preparations are not as popular as the combined 
preparations since their efficiency is not so high and also the 
menstrual cycles are not as regular15.
The administration o f an estrogen and a progestin in combination 
preparations could interfere with fertility in several ways. It is clear 
though, that the mixture inhibits ovulation. Ovulation could be 
prevented either by inhibiting the ovulatory stimulus o r by 
preventing the growth o f follicles, and this agrees w ith the 
experimental observation that follicular growth and ovulation can be 
prevented by either estrogen or progesterone given singly. The 
orally active progestins alone have been administered because o f the 
fear that estrogen may have harmful effects. Continuous
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administration o f a progestin in sufficient dose abolishes the cycle for 
as long as it is given and leads to ovarian and endometrial atrophy. 
Very small doses may alter the structure o f the endometrium and the 
consistency o f the cervical mucus without disrupting the cycle or 
inhibiting ovulation.
Long acting progestins, given by intramuscular injection, are also 
effective. Additional forms o f contraception also utilise the highly 
active, purely progestational compounds to provide vaginal 
absorption, in intrauterine devices, or in plastic capsules for 
subcutaneous application.
There are many side effects connected to the use o f  oral 
contraceptives, some o f which are quite major and others which are 
less significant such as nausea, vomiting and headaches. The most 
important side effects to be aware o f are the cardiovascular side 
effects and the induction or promotion o f tumours. Although these 
seem alarming, they are not well substantiated and in fact the oral 
contraceptive can actually lower the incidence o f certain disorders. It 
can be said that in most ways, the advantages o f the oral 
contraceptives outweigh the disadvantages.
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o1.13 Anti-hormones
Steroid hormone receptor antagonists can be defined as compounds 
which bind with high affinity to the receptors so as to exclude the 
native steroid hormone from occupying its binding site and also 
which do not themselves lead to any hormonal agonist effect. 
Compounds o f this kind which bind to the receptors for estrogens, 
androgens or mineralocorticoids have been in clinical use for some 
time, but until recently receptor antagonists for progesterone and 
glucocorticoids have been more elusive.
The first major clinical advance in the field  o f anti-androgens 
resulted from  studies o f the 1,2-methylene substituted steroid 
cyproterone acetate (18).
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Many other steroids have been investigated for their anti-androgenic 
characteristics, but few have progressed further then the initial 
identification o f their activity16.
Early attempts17 4  8 to synthesize progesterone antagonists by 
introducing bulky substituents at positions 1, 7 and 17 (4 ) o f active 
progestins failed.
Researchers at Roussel-Uclaf made a major breakthrough in the 
search for effective progesterone antagonists. They found that 
certain 11-aryl steroids showed both antiglucocorticoid and 
antiprogestional activities. This indicated the existence o f a much 
larger 'pocket' than expected in the receptor molecule above C - l l  o f 
the bound steroid19. Similar results were also reported by workers 
at Schering20.
Several hundred compounds with 11-aryl substitution have been 
sythesized 21»22 and among these 3 derivatives, RU 38486,(19) ZK 
98.734,(20) and ZK 98.299, (21 ) showed particularly strong 
properties as antiprogestins. Progesterone is crucial to the 
maintenance o f pregnancy, and the analogues can serve as a means o f 
interrupting pregnancy.
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Under the name 'mifepristone'. RU 38486 is administered orally 
(600mg), followed after 2 days by a small dose o f a prostaglandin 
(e.g. sulprostone or gemeprost), which increases the frequency and 
strength o f  the uterine contractions needed to expel the embryo. In 
many countries including the UK, the drug combination is now 
approved for ending pregnancies o f up to 49 days duration (counting 
from  the first day o f the last menstrual period). This procedure is 
now a favourable approach to the termination o f pregnancy.
Many women in developing nations and, to a lesser extent, in 
industrialized countries, rely on pregnancy interruption for birth 
control. Although legal surgical methods are safe and effective, they 
have well-known drawbacks. In the first three months o f pregnancy, 
vacuum aspiration (sometimes preceded by dilation o f the cervix) is 
the usual method o f choice. In this approach, suction is applied to 
rem ove the embryo and the endometrial tissue in which it is 
embedded. After about three months o f pregnancy, the required 
precedures generally become more complex. As pregnancy 
progresses, the risks o f infection, haemorrhage, scarring and impaired 
fertility increase. In developing nations, where surgical facilities are 
often inadequate, the danger is greater. What is worse, where legally 
operated facilities are not readily accessible, many women die from 
having unsafe abortions, typically because o f uncontrolled bleeding or 
infection.
Results also suggest that RU 38486 has potential as an emergency 
post-coital contraceptive with a wider range o f action than the 
currently used hormonal preparations which need to be administered
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within 48-72 hours after unprotected intercourse. Nevertheless, 
treatment as early as possible seems advisable because it would 
appear that efficiency decreases after implantation has commenced.
Binding to steroid hormone receptor and plasma proteins
1.14 Progesterone receptor
It has been demonstrated that RU 38486 (19), ZK 98.734 (20) and ZK 
98.299 (21) show specific, high-affinity binding to progesterone 
receptor preparations from a variety o f species including rat ovary,23
rabbit uterus,2 4 Ca lf uterus and human endometrium and 
myometrium.
In general the relative binding affinity o f these antiprogestins is 
lower than that o f progesterone in assays involving a relatively short 
(1-3 hours) period o f incubation. However, RU 38486 dissociates 
more slowly from  the receptor than progesterone25 and its relative 
binding affinity is substantially greater than that o f progesterone 
when incubation period is prolonged. It is unclear whether or not the 
presence o f  b io logica lly  active m etabolities influences the 
antiprogestational activity o f RU 38486.
1.15 Glucocorticoid receptor
RU 38486 (19), ZK 98.734 (20) and ZK 98.299 (21) also bind very 
strongly to the glucocorticoid receptor o f various tissues and species. 
The ability o f antiprogestins26 to interact with both the progesterone
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and glucocorticoid receptor is not surprising in view o f the more than 
50 percent homology in amino acid composition that exists between 
these two receptors in their C-terminal end, the region which is 
thought to be involved in steroid binding.
Because o f its antiglucocorticoid propeties, RU 38486 has been 
employed orally in clinical treatment o f Cushing's syndrome and 
adrenal cancer, while topical application o f the compound may have 
potential in the therapy o f certain forms o f glaucoma and ocular 
hypertension.
1.16 Other steroid hormone receptors
The synthetic steroid analogue RU 38486 (19) binds to the androgen 
receptor o f the rat prostate and rat ovary but with lower affintiy 
than testosterone when given orally to castrated male rats. RU 38486 
causes a dose-dependent inhibition o f the increase in weight o f 
seminal vesicles and prostate induced by testosterone propionate but 
this antiandrogenic activity is 20-30 times weaker than the 
compound's antiprogestational and antiglucocorticoid activities in the 
rat. Both o f the synthetic steroids ZK 98.734 and ZK 98.299 also 
exhibit weak binding affinity for the androgen receptor o f rat 
prostate, but are potent antiprogestins. The ability o f antiprogestins 
to bind to the androgen receptor is probably due to the structural 
homology that exists in the putative steroid binding region o f rat and 
human androgen receptor and, on the other hand, the human 
progesterone receptor.
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1.17 Receptor binding bv 13<*-methvl steroids
There is a high affinity o f the 13<* -methyl compounds for both 
progesterone and glucocorticoid receptors27. Results obtained with a 
large number o f synthetic steroids with normally configured 
skeletons provide information concerning the atoms most critical for 
binding to the receptor protein. For example, Seeley et al28 
demonstrated that, in addition to hydrogen bonding with the 3 and 
20 ketone groups, van der Waals' interactions at carbons 2,4,7,9,12,18 
and 19 can normally be expected. The conformation o f the A  and B 
rings in particular can therefore be expected to influence receptor 
binding. In the case o f the 11-aryl derivatives, it might also be 
anticipated that the allowed variation in orientation o f the phenyl 
ring with respect to the rest o f the molecule will be limited by the 
size and shape o f the hydrophobic domain on the protein with which 
this group interacts. In order to gain a more detailed analysis o f 
these structural differences, X-ray crystallographic analysis o f a 13- 
epim eric pair has been examined. For this purpose, the 4- 
fluorophenyl derivatives (22) and (23) were chosen.
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The basic results indicate a close similarity in molecular shape (Fig 
1.9) and it can be seen that the relative positions o f the 3-keto group 
and carbon atoms 3-6, 10 and 11 are virtually unchanged, which 
suggests that tha A-ring will be able to interact quite normally with 
the receptor. The relative orientations o f the fluorophenyl group in 
the two compounds are also quite similar. The major changes involve 
the C and D-rings, as would be expected, and carbon atoms 7 and 8. 
From both X-ray crystallographic and protein-binding studies, it is 
known that these regions o f the molecule are less intimately involved 
in receptor interactions (Seeley and Duax et al)28»29, so that the main 
features o f these two steroids are compatible with current notions o f 
the receptor protein. It is worth noting however, that the 17- 
hydroxyl groups in these compounds, 17K in the natural epimer and 
17<Xin the 13 -methyl derivative, occupy quite different positions. 
The clear differences found in the biological activities o f all these 
compounds indicate that these groups play an important role in their 
activity, most likely at the receptor level, and this implies that there 
are receptor sites for hydogen bonding with the hydroxyl groups o f 
the 13c<-methyl isomers which do not interact with progesterone.
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Fig. 1.9
1.18 Termination o f early pregnancy
Oral administration o f RU 38486 either in a single dose or for three 
consecutive days starting on the day o f implantation (day 6 post- 
coitum) is capable o f terminating pregnancy in the rat and mouse^^ 
A  reduction in the 100% effective dose can be achieved by using 
a lternative  routes o f  drug adm inistration (subcutaneous, 
intramuscular and intravaginal). Comparative studies have shown 
that RU 38486, ZK 98.734 and ZK 98.299 have comparable potency at 
this early stage o f pregnancy in rats and guinea pigs.
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1.19 Termination of more advanced pregnancy
In the rat, oral doses o f RU 38486 similar to those that interrupt 
early pregnancy also terminate more advanced pregnancies except on 
day 15, when there appears to exist a relative insensitivity to the 
abortifacient activity o f the compounds^ The lack o f dose- 
dependency and the higher efficiency o f sequential treatment with 
antiprogestins and the prostaglandin analogue sulprostone are also 
found in human pregnancy termination. The mechanisms through 
which antiprogestins induce abortion at later stages o f pregnancy 
have been studied extensively in the guinea pig. A t the level o f 
myometrium, antiprogestins cause a dramatic, approximately 30-fold 
increase in the sensitivity to sulprostone which, in the case o f ZK 
98.299 is maintained for 24 hours
Despite the intensive changes caused by antiprogestins alone, 
abortion only occurs several days later and it is often incomplete or 
does not take place at all. This situation which seems somewhat 
contradictory, is called the 'antigestagen syndrome' and is generally 
considered to be due to the lack o f mymometrial contractions 
resulting from insufficient endogenous PG production which, in turn, 
is thought to be due to the inhibition o f progesterone by the 
administered antiprogestin.
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CHAPTER 2
Anti-progestins
2.1 Introduction
Anti-progestional compounds were developed in the 1970’s, and a 
number o f steroids were subjected to screening procedures in order to 
determine what structural features would lead to inhibition o f binding 
o f radio-labelled progesterone or other progestins to the progesterone 
receptor. The Roussel-Uclaf group in France synthesised somel 1-aryl 
steroids in the search for anti-glucocorticoid activity. Some o f these 
new compounds, which included RU 38486, proved to be active as 
anti-glucocorticoids but more notably, they also proved to be very 
potential anti-progestins.
Following the discovery o f the first com petitive progesterone 
antagonist RU 38486, there has been an intense search for more 
potent and more selective anti-progestins. Among several hundreds 
o f compounds under preliminary investigation by Schering are ZK 
98734 and ZK 98299. Similarly related compounds to RU 38486 have 
been synthesised by Organon. Among the Organon compounds, 
compounds (2.1), (2.2) and (2.3) are the most interesting ones. All 
these compounds do not only differ in relative potency, but are clearly 
distinguished by their different behaviour in various animal models.
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a NMe2 H ch3 Saturated
b NMe2 H ... Unsaturated
c H NMe2 ch3 Saturated
d H NMe2 Unsaturated
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2.2 Synthesis of anti-progestins
Teutsch and his co-workers devised a general method for the synthesis 
o f 11-substituted 19-norsteroids, using the conjugate opening o f allylic 
epoxides by organo copper reagents ^  Fig(2.1).
z z
(2.5)
Fig. 2.1
The suggested mechanism for the organocuprate reagent is shown in 
Fig (2.2) and involves initial nucleophilic displacement o f the epoxide 
at C io  followed by an allylic rearrangement.
The preparation o f RU 38486 involves the initial preparation o f the 
intermediate compound (2.16) from estradiol methyl ether (2.10) Fig 
(2 .3). This is followed by the introduction o f the 11-substituent 
following Teutsch’s method to afford compound (2.17). Treatment o f 
compound (2.17) with a suitable lithium acetylide gives compound
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(2.18). Finally, appropriate hydrolysis o f compound (2.18) affords RU 
38486(2.19) (Fig 2.3).
(2.9)
Fig. 2.2
OH
OH OH
CN
OH
( 2 . 1 5 )
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Fig. 2.3
For preparation o f ZK 98734, the method involves a modification o f 
the general and efficient strategy devised21 for the synthesis o f 11- 
substituted estra-4, 9-dienes. The starting material is the Birch 
reduction product o f estradiol methyl ether, fo r which appropriate 
hydrolysis leads to the deconjugated enone ( 2.12), which by a 
bromination-dehydrobromation sequence is transformed to the 
dienone (2.13) (Fig 2.3). Ketalization o f  this compound (Fig 2.4)
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proceeds with a double bond shift to form the 5(10), 9 (ll)-d ien e  
(2.20), which is epoxidised to form 5<*<,106<- epoxide (2.21). The next 
step is the introduction o f thel lft-substituent which is conveniently 
achieved by reaction with^-dim ethyl amino phenyl lithium. 
Compound (2.22) undergoes Oppenauer oxidation to the ketone (2.23), 
which is treated w ith the lith io deriva tive  o f  propargy l 
terahydropyranyl ether to give compound (2 .24 )(R - CH20THP). 
H ydrogenation  fo llow ed  by acid-catalysed deprotection - 
dehydration^ leads to compound ZK 98734 (20).
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ZK 98299
Fig. 2.4
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Alternatively, after Oppenauer oxidation,the next step in the 
preparation o f the ZK 98299 is the photolysis o f the intermediate 
(2.23) with the full spectrum o f a mercury high pressure lamp in 
acidified dioxan. By Norrish-type 1 cleavage and recombination, 13*'- 
methyl-gonane^(2.26) is obtained in good yield.
The side chain at 017  is constructed by adding the lithio derivative of 
propargyl tetrahydropyranyl ether. In contrast to the behaviour 
observed in the natural estrane series, nucleophilic attack at C-17 in 
the ketone (2.26) is not very highly stereoselective, giving isomers 
with predominant formation o f the 17£-adduct (2.27).
Hydrogenation o f this compound followed by acid catalysed 
deprotection-dehydration gives compound ZK 98299 (21).
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2.3 Mechanism of action of anti-progestins
The cellular mechanism o f action o f anti-progestins is not particularly 
clear. Several studies have been carried out in order to explain the 
absence o f significant agonist activity despite high receptor binding 
affinity o f these compounds, These studies have been conducted on 
the physiochemical characteristics and DNA-binding ability o f 
glucocorticoid and progesterone receptors bound to antiprogestin. 
Because the ligand-receptor interactions are usually studied under 
non-physiological, cell-free conditions as opposed to in intact cells, the 
studies have yielded conflicting results^.
Recently, a model o f the molecular basis o f hormone antagonism has 
been proposed by Groger et al,^4 which reconciles some o f the 
divergent findings reported previously. In this model (Fig 2.5), the 
unliganded, non-DNA-binding 8S form o f the receptor is a hetero­
oligomer consisting o f the 4S steroid-binding unit 'R' and the non 
steroid-binding, non DNA-binding heat-shock protein 'hsp 90' which is 
common to all classes o f 8S receptors. Binding o f the native hormone 
or hormone agonist 'H' to the receptor triggers a conformational 
change with release o f the hsp 90 sub-unit and unmasking o f the 
DNA-binding site on the ’activated' 4S receptor. In contrast to this, 
the R-hsp 90 complex is stabilised when the antihormone 'Ah ' binds
to the receptor. Also the hsp is not released and DNA-binding does 
not occur. In (Fig 2.5), an alternative model suggets that binding o f 
the antihormone to the receptor is capable o f  provoking a
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transformation with dissociation of hsp 90 from  the 4S subunit. 
However, the latter does not undergo the conformational change 
required for optimal DNA-binding and induction of gene transcription.
It is important to note that both models are not necessarily mutually 
exclusive and that both mechanims can be operative in vivo, either 
concomitantly or at different times, depending on the physiological 
status o f the cell.
Fig. 2.5
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CHAPTER 3
Steroidal Anti- androgens
3.1 Biological Studies of Steroidal Anti-androgens
The most common anti-androgens include cyproterone acetate (18) 
and flutamide (3.1). It can be seen from (18) that cyproterone 
acetate, like many anti-androgens, has a basic steroid skeleton 
whereas flutamide is not a steroid.
ch3
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The biological actions o f cyproterone acetate result from  blocking 
active androgens from interacting with their target organ intracellular 
receptors. Estrogens are also capable o f generating antiandrogenic 
responses and these effects are largely mediated by either inhibition 
o f testicular androgen secretion via blocking the secretion o f LH or by 
a direct suppression o f testosterone synthesis by Leydig cells. 
Cyproterone acetate has progestational activity, which enables it to 
have an inhibitory feedback effect on the hypothalamus, as well as
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giving it the properties o f an androgen antagonist. In contrast, 
cyproterone itself has no progestational activity and promotes 
hypothalamic stimulation by inhibiting the negative feedback 
inhibition o f testosterone. Cyproterone is much less active as an anti­
androgen than its acetate3
Cyproterone acetate has been extensively investigated and used 
clinically for the management o f prostate carcinoma, for the reduction 
o f acne in both sexes and hirsutism in women, in the therapy o f 
precocious puberty, to delay premature sexual and physical 
maturation and for the reduction o f libido in men with severe 
deviations in sexual behaviour. Cyproterone acetate has been 
investigated as a male contraceptive agent, shutting down 
spermatogenesis. However, all anti-androgens have many undesirable 
side effects and these include consequent loss o f testosterone 
production from the Leydig cells, leading to loss o f potency and libido, 
and breast changes in the male (gynaecomastia).
Apart from cyproterone acetate and A-norprogestron, many other 
steroids have been investigated and/or used for their anti-androgenic 
character. However, whilst more than 200 anti-androgens have been 
reported, only a few  have progressed further than the initial 
identification o f their activity36-39. The ring-A oxa-steroid,6<X- 
bromo-17 fi-hydroxy-17 <X-methyl-4-oxa-5 <X-androstanan-3 -one 
exhibits anti-androgenic effects in all androgen dependent tissues 
outside the central nervous system40»41, competing for DHT binding
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sites slightly more selectively than does cyproterone acetate. Other 
steroids with high effectiveness in competing for DHT receptors 
include 17R-hydroxy-2-oxa-4,9-estradien-3-one and 17ft-hydroxy- 
170<-methyl-2-oxa-4,9-estradien-3-one, although they showed some 
androgenic as well as anti-androgenic character. The highest degree of 
inhibition seemed to be associated with compounds showing a general 
flattening o f ring geometry.
Alkylations o f the A-ring o f testosterone appear to mainly give rise to 
compounds with varing degrees o f androgenicity. However, 2<X- 
methyltestosterones with a 17-<X-ethynyl or 17<X-vinyl group are 
claimed to show progestational and anti-androgenic qualities14.
A  group at Upjohn observed that introduction o f a 7<X-methyl group 
onto 19-nortestosterone resulted in increases in both anabolic and 
androgenic activity42 . Recently, attention has focussed on the 
possible anti-androgenic, anti-fertility effects o f 7R-methyl-19- 
nortestosteroneJ •
Flutamide is a non-steroidal antiandrogen that has no other hormonal 
activity. The predominant effect o f flutamide is the enhancement of 
the frequency o f pulses o f LH secretion. Therefore, while the drug is a 
pure antiandrogen, the rise in plasma testosterone serves to limit its 
antiandrogenic effects. Consequently, flutamide is most useful to 
inhibit the action o f adrenal androgens in castrated men or in men 
receiving GnRH continuously or in situations in which LH production is
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not under predominant control o f androgen. The principal clinical 
application o f flutamide at present is in the treatment o f prostatic 
cancer, usually in conjunction with GnRH blockade or estrogen.
It has also been used experimentally in combination with an oral 
contraceptive for the treatment o f hirsutism in women.
3.2 Synthesis of anti-androgens
Various methods for preparing 7-alkylated steroids have been 
reported in the literature44'47. The method described by Campell 
and Babcock4  ^ involving Michael addition o f methylmagnesium 
bromide to 6-dehydro-17 <X-methyl-testosterone (3.2) in the presence 
o f cuprous chloride gave 7o<, 17 <X-dimethyl-testosterone (3.3) as the 
main product and a small amount o f the 7ft-epimer(3.4) (Fig3.1). On 
dehydrogenation o f the crude product with chloranil, the minor 
com ponent (3 .4 ) was converted into 6-dehydro-7, 17<X- 
dimethyltestosterone (3.5) which was separated from  7<X-methyl 
enone (3.3) and then reduced back to 7ft-methyl enone(3.4) with Li- 
N H 3 . The 7<X-epimer does not undergo dehydrogenation with
chloranil.
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7ft-Methyltestosterone has been prepared by Zderic and R ingo ld^  by 
the addition o f methyl Grignard reagent to 7-ketotestosterone 
ethylene ketal acetate (3.6) (Fig3.2).
When the total crude product o f the Grignard reaction was treated 
with hot aqueous acetic acid , 7-methyl-6-dehydrotestosterone (3.7) 
was obtained in excellent yield. This was hydrogenated with 5% 
palladium carbon catalyst in methanol-KOH mixture to give 7 ft- 
methyltestosterone (3.7).
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Fig. 3.2
Another method for preparing 7R-alkylated steroids and 6- dehydro- 
7-methyl steroids has been described by Robinson and co-workers^ 
Fig (3 .3 ). When the 7-ketone (3.9) was treated with methyl- 
magnesium iod ide or, preferably, methyl lithium  in ether- 
terahydrofuran mixtures, compound (3.10) was formed.
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This triol underwent Oppenauer oxidation and dehydration to give 
dienone (3.11) which was oxidised with chromic acid to compound 
(3.12) 7-methylpregna-4,6-dien-3,20-dione, in good yield. Finally 
hydrogenation o f the diene (3.12) in benzene with palladium 
strontium carbonate catalyst gave 7ft-methylprogesterone (3.13) in 
poor yield.
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CHAPTER 4
Nor-steroids
4.1 A- Nor- steroids
A-nor- steroids with one carbon atom missing from the A ring
Several A-nor steroids have been prepared by ring contraction 
procedures carried out on derivatives o f testosterone, 19- 
nortestosterone, progesterone, cortisone and others, and have shown 
anti-hormonal properties4^. For example, A-nor-progesterone (4.1) 
possesses anti-androgenic activity.
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(4.1)
Fig. 4.1
It has been observed by Raynaud et al50 that a certain class o f 
antiestrogens appear to exert their antagonistic activity from the fast 
dissociation o f the complex they form with the estrogen receptor 
compared to that o f the natural hormone. The relative binding 
activity o f such compounds is high but it declines with prolonged 
incubation.
Antifertility effectiveness in adult cycling female baboons was 
investigated using 2<X, 17<x-diethynyl-A-nor-5o<-androstane-2R, 17ft.
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diol (anordrin 4.2) and 2<X, 17<X-diethynyl-A-nor-50<-estrane-2ft, 
17£-diol (dinordrin 4.3), or its 2ft-ethynyl-isomer (dinordrin II).
4.2 B-Norsteroids
B-Nor analogues o f testosterone, dehydroepiandrosterone, 17<X- 
methyltestosterone, 4-androstene-3,17-dione, 5-androstene-3£,17K- 
d io l, 3<X-hydroxy-5<X-androstan-17-one and 17jWiydroxy-5<X- 
androstan-3-one were either extremely weak androgens in chick 
comb test or fully inactive in biological assay. These findings indicate 
a considerable decrease in androgenicity as a result o f elimination of 
one carbon atom from  ring B. However, the B-nor form o f 17<X- 
methyltestosterone was active as an antiandrogen and marginally 
active antiandrogens were free B-nor-deoxycorticosterone and its
ci
acetate0 .
Potential hormonal activity was sought in various B-norsteroid, 
analogues o f corticosteroids, estrogens and androgens, by examining
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the displacement ability o f an appropriate radioligand from receptor 
binding. The binding properties were compared with parent 
hormones with normal steroid nucleus. Glucocorticoids B-norcortisol 
and B-nor-11-deoxycortisol, if  compared in terms o f their binding to 
rat liver cytosol, show a decrease in binding ability o f about three 
orders o f magnitude relative to corticoids without contraction o f ringB.
The binding o f 1 lft-hydroxy- and 11 -oxo-B-norprogesterone was 
quite negligible in contrast with a relatively high binding o f 11ft- 
hydroxyprogesterone51.
A  similar situation was found for estrone and estradiol-17ft and their 
noranalogues. In B-norestrogens, a lower ability to displace 3H- 
estradiol-17ft from uterine cytosol receptors was found than in Cqg- 
S2estrogens0 .
4,5-Cyclo-A-homo-B-nor-androstane derivatives ( Fig4.2, compounds 
4.4-4.6) were assayed in vivo on mice for their androgenic and anti- 
androgenic activity, and the effect was compared with that o f 
cyproterone acetate. The inhibition o f dihydrotestosterone binding to 
rat prostate cytosol by the compound correlated with the in vivo 
effects. The antiandrogenic activity^ »54 0f i7£-acetoxy-4<X,5-cyclo- 
A-homo-B-nor-5 <X-androst-1 -en-3 -one was found to be comparable 
with that o f  cyproterone acetate. It was also antirenotrophic but 
unlike cyproterone acetate it was lacking antianabolic activity and 
corticoid-like action on relative weight o f spleen.
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A  lower antiandrogenic activity was found for 17ft-hydroxy- 17 c<- 
methyl-4o<,5-cyclo-A-homo-B-nor-56<-androst-l-en-3-one, whilst 
the remaining three compounds (4.1,4.2,4.3) with saturated ring A  
were only very weak competitors for dihydrotestosterone binding in 
prostate and for testosterone action in vivo in accessory sex organs^.
O.Ac O.Ac
OH
Fig. 4.2
4.3 A- or B- homosteroids
There have only been three reports56>57,58 on a serjes Gf  A-homo- 
and B-homo-androstane and pregnane derivatives (Fig 4.3,compounds 
4.7-4.18).
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The steroids with expanded rings A  or B were tested for potential 
androgenic or antiandrogenic activity by binding assay on rat 
prostate cytosol receptors. The binding to sex hormone binding £- 
globulin and the inhibition o f 5<X-reductase was measured as well.
The results o f the in vitro screening were compared with in vivo 
bioassay. Though a very weak binding activity and reductase 
inhibition was found in several steroids with expanded rings A  or B, a 
weak androgenic rather than antiandrogenic activity was observed in 
them. It was found that, in general, compounds with deformed planar 
configuration due to A- or B-ring expansion or to a change in A/B- 
ring annellation (4.7 and 4.8), do not show much agreement o f the 
bioassayS 9 results with the data obtained with screening by in vitro 
tests for the biological activity60.
nu O
O O
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4.4 Secosteroids
The importance o f the features o f planarity and molecular rigidity^ * 
both for receptor affinity and for biological activity was demonstrated 
in a series o f 5,6-seco-and9,ll-secoestradiols, representing flexible 
analogues o f the parent prototype/ 17£-estradiol. The relative binding 
affinities o f these derivatives were compared with their uterotrophic 
and anti-implantation activity. A  considerable decrease o f  relative 
binding affin ity was found for d,l-5,6 seco-17fc-estradiol (95% 
compared with estradiol) and for d-9,11-seco-17ft-estradiol ( 25.2% ) 
which have an increased degree o f rotational and vibrational freedom
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in the region o f rings B and C compared to that o f estradiol. 
Comparable relative binding affinities o f isomers o f d, 1-5,6-seco- 
estradiol ( 8&-H 7.95% and 8<X-H 5.06% ) are noteworthy, since the 
latter correspond to 8-iso- 17ft-estradiol which has been found to have 
fairly high receptor affinity50.
Antiandrogenic activity was tested by bioassay for 3-oxo-5,10-seco- 
steroids(4.19). Their antihormonal activity is the expression o f their 
irreversible inhibition o f 5<X-reductase°^. They are powerful non­
com petitive inhibitors o f rat epididymal and human sex skin 
fibroblast 5<X-reductase but very  poor inhibitors o f  3<X- 
hydroxysteroid dehydrogenase05. For 5 c<-reductase the inhibition 
constant for 5 ,10 seco-estra-4 ,5-diene-3,10,17-trione(4.20) was 
5.47mol/l in epididymus and 1.60 mol/1 in fibroblasts, and for 
5,10,20- trione 0.90 mol/1 and 0.53 mol/1 per litre, respectively. 
The former secosteroid has a closely similar conformation to that o f 
4-androstene-3, 17-dione0^ and for the latter conformational 
similarity analogous to progesterone was presumed05.
OH o
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4.5 Other Modifications of Ring A or B.
A  6-membered ring A  attached to ring B in position 6 in 17ft- 
hydroxy-3, 6-cyclo-A-nor-3,5- seco-6ft-androstan-3-one, compound
(4.7) caused a high binding to rat prostate cytosol receptors for 
dihydrotesterone and relatively high antiandrogenic activity*^.
A  lower antidrogenic activity was exhibited by its 5-oxo derivatives
(4.8) and by two compounds related structurally to cyproterone 
acetate, namely 17<X-acetoxy-5,7ft cyclo-B-homo-5ft-pregnane-3,20- 
dione (4.21) and its 5,7<X- cycloisomer (4.22). Various 3,5 and 5,7o<- 
cyclosteroids were checked for antiandrogenic activity**7 and binding 
to rat prostate cytosol or sex hormone binding globulin and in some 
also for inhibition o f 5<X-reductase with the aim to find structures 
similar to cyproterone acetate with comparable useful biological 
effects**®. In spite o f the demonstration o f several relatively potent 
antiandrogens, cyproterone acetate remains the superior compound 
among the antiandrogens with a wide application for therapeutic use 
as testified by numerous publications**^.
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4.6 C- Norsteroids
The quest for anti-inflammatory steroids possessing increased activity 
or lacking side-effects has included several modifications o f the 
hydrocortisone molecule. O f these, the introduction o f 6<X- or 16- 
methyl substituents has been particularly e ffective70 . Also the 
demonstrated enhancement o f activity due to the 12<x -halogen 
substituent provided further impetus to the synthesis o f a steroidal 
dervative methylated at position 12.
Although several procedures for the insertion o f the 12<X-methyl 
functionality might be envisioned, the addition o f a methyl 
organometallic to an l l f t -12ft-epoxide appeared to be the method o f 
choice. The known diaxial opening o f 5,6-epoxide with methyl 
Grignard reagents suggested that the desired llft-hydroxy-12o< 
-methyl grouping would be the expected product o f such an addition. 
Furthermore, the anticipated conversion via the 11-ketone to the 
equatoria l 12ft-epimer, which was expected  to be the 
thermodynamically more stable isomer, also would make the 12ft- 
methyl derivatives available. Accordingly, 11 ft, 12 ft-epoxypregnane- 
3,20-dione 3,20-bis-(ethylene ketal) was prepared by the following 
route.l2<X-Bromopregnane-3,ll,20-trione71 was converted to the 
corresponding 3,20-bis(ethylene ketal) with ethylene glycol and / -  
toluenesulphonic acid72. Because o f the loss o f bromine during 
reduction  o f  steroidal bromo-ketones w ith  certain  other 
hydrides7^,7<^  lithium borohydride was used in the preparation o f the
bromohydrin. This compound was not isolated as a crystalline
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intermediate, but was transformed immediately to the desired 
l l f i ,12&-epoxide (4.25).
The action o f methyl Grignard reagents in opening 5,6-epoxides has 
been the subject o f several investigations75, but their action upon 
other steroidal epoxides has remained largely unexplored. When 
(4.25) was treated with methylmagnesium iodide in refluxing 
benzene, a crystalline product was obtained which gave the correct 
analysis for the desired bisketal (4.26).
Fig. 4.4
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4.7 Anordrin
As early as 1962, Pincus at al., reported that some A-nor-steroids 
exhibit both anti-progestational and estrogenic activity when 
administered to rats and mice, opening up possibilities o f their use as 
anti-implantation agents70' 7^.
OR C S Q I
4.27 . R  = H ( A nordiol)
4.2 » R = COEt (A nord rin )
4.29 . R  = C0CH2CH2C02H
Since the late 1970's, there has been a revival o f interest in the 
biological properties associated with these A-nor-steroids, following 
publication by Chinese investigators who reported that a significant 
anti-fertility activity80 is associated with the dipropionate o f 2,17<X- 
diethynyl-A-nor-5-androstane-2ft,17£-diol(4.2), used as a mixture o f 
isomers at position 2. It was reported to be as effective as estrogens 
in preventing pregnancy in rabbits and hamsters when administered 
in the period 1-3 days after mating but before implantations 1.
Anordrin has a relatively small estrogenic activity whilst showing 
anti-estrogen, anti-progestin and anti-androgen character as a result
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o f competitive binding to the respective hormone receptors. Anordrin 
and also its bis-hemisuccinate analogue are hydrolysed in vivo to 
anordiol,(4.27) but in view o f the complex hormonal/anti-hormonal 
p ro file  o f  these steroids, their precise mechanism o f action as 
postcoital anti-fertility agents has remained controversial and the 
wider adoption o f anordrin as a clinical contraceptive drug has been 
discouraged by concerns about the possible health risks o f estrogenic 
steroids.
The synthesis o f anordrin8 2 iS described in Fig(4.5) involving a 
reaction between potassium acetylide and A-nor-androstane-2,17- 
dione (4.30) in which an attack occurs selectively from the alpha face 
o f C-17 due to the steric effect o f the 18-methyl group at the less 
hindered C-2 position, producing a mixture o f 2<X-ethynyl (4.2) and 
2fi-ethynyl (4.31) isomers.
o o
AcO
C r 0 3 ,H 0 A c - H 2S 0 4
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F ig . 4 .5
Crabbe et al83 have prepared the two separate isomers o f anordrin 
and also synthesised the analogous compounds lacking the 19-methyl 
group, which they named dinordrin I and II.
The starting material for the dinordrins was 19-nor-testosterone (Fig 
4.6, compound 4.32), which was converted to 2-keto-dinor-steroid 
(4.33) by conventional techniques. Oxidation o f the 17-hydroxyl 
group in the intermediate (4.33) provided the corresponding 2,17- 
diketo-dinor-steroid (4.34) which was treated with an excess o f 
lithium acetylide-ethylenediamine complex to afford a 3:2 mixture of 
th 2<X-ethynyl compound (4.35) and its 2£-epimer (4.36) separated 
by preparative TLC. Esterification o f the tertiary hydroxyl groups of
diols (4.35) and (4.36) with propionic anhydride provided the 
dipropionates (4.37) and (4.38).
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4.8 Postcoital use of anordrin and RU 38486 for prevention of
implantation in the rat
A  study by Chang, Wang and Bardin84 was recently carried out to 
determine whether RU 38486, anordrin or anordiol, alone or in 
combination, could prevent pregnancy when administered prior to 
implantation on postcoital day 2.
RU 38486 synergises with anordrin and the d io l which is its 
hydrolysed metabolite to terminate pregnancy . The interaction o f 
these agents was studied at two days postcoitally in the rat. RU 38486 
at a dose o f 4 mg/kg did not prevent pregnancy, as determined by 
autopsy 12 days post insemination. A non-effective dose o f RU 38486 
(2-4 mg/kg) combined with a non-effective dose o f anordrin (1.25-2.5 
mg/kg) prevented pregnancy in all animals treated and there was no 
evidence o f implantation sites or embryos when the animals were 
examined on day 12 post insemination. The same synergistic effect 
was observed when a small dose o f RU 38486 (1 mg/kg) was 
combined with 0.6 mg/kg anordiol.
When investigating pregnancy prevention, animals were treated two 
days post coitally with 4 mg/kg o f RU 38486 and 2.5 mg/kg o f 
anordrin or 2 mg/kg o f RU 38486 and 0.6 mg/kg o f anordiol, and 
were killed at short intervals after treatment. These drugs had no 
effect after 6 hours, but the numbers o f embryos in oviducts were 
significantly reduced 12 hours after treatment. By 24 hours following 
treatment, no embryos were recovered from either the oviduct or the
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uterus. Progesterone and estradiol levels in serum collected 24 hours 
after treatment were not significantly different from those o f controls.
These findings demonstrate that combinations o f RU 38486 with 
either anordrin or anordiol synergise to prevent pregnancy in the rat 
when administered postcoitally.
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CHAPTER 5
STRATEGY FOR THE SYNTHESIS OF POTENTIAL NEW ANTI- 
PROGESTINS
This research project involves the synthesis o f a new steroid which it 
is hoped will function as an anti-implantation agent.
5.1 BACKGROUND
The first orally active, synthetic progestin was discovered when 
Djerassi»s group at Syntex combined the beneficial effects o f removal 
o f the 19-methyl group and attachment o f the 17-ethynyl function. 
The incorporation o f these functionalities resulted in the desired 
combination o f high progestational potency and good oral activity in 
norethisterone, used in the contraceptive pill.
Similarly, combinations o f structural features have been very 
successful in the development o f highly potent and selective 
glucocorticoids. Therefore it seems to be a rational approach to search 
for new anti-progestins having increased potency, compared with RU 
38486, by seeking to combine individual structural features which 
may contribute to strong, antagonistic binding to the progesterone 
receptor.
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There are a number o f different ways to try to identify new drugs 
which function by interaction with specific biological receptors. The 
least scientific method is to establish a random screening program. 
This method is very expensive and does not have a particularly good 
success rate. However, it is sometimes used by pharmaceutical 
companies in the absence o f other good leads and has the one distinct 
merit that it may turn up entirely novel structural types since it 
makes no presumptions about structure- activity relationships.
Another approach is to take an already identified lead compound and 
make as many as possible o f its close structural analogues. This 
m ethod is also is very expensive but is frequently used by 
pharmaceutical companies.
Two important developments in the field o f post-coital contraceptives 
have taken place in recent years.
1. The Roussel-Uclaf pharmaceutical company in France discovered 
that the introduction o f a 4 - (N,N-dimethylamino) - phenyl group at 
the 11-position o f certain steroids gives them anti-hormonal 
properties. In particular, RU 38486 (19) is a potent anti-glucocorticoid 
and is also an anti-progestin. It is now in widespread clinical use as an 
anti-implantation agent.
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(19)
2. In the Peoples' Republic o f China, a compound called anordrin 
(4.3,R=Me) has been developed and has been used clinically as a 
"Visiting Pill" or "Vacation Pill". It is popular with many Chinese 
couples who are assigned work in different towns and meet only 
infrequently fo r short periods. It is taken for a few  days after 
intercourse and has a high effectiveness, apparently acting as an anti­
implantation agent. However, anordrin possesses some estrogenic 
character which is undesirable, since estrogens are associated with 
nausea, breast swelling and a possibly increased risk o f thrombosis 
and cancer. The 19-nor-analogue has also been made and is an even 
more potent anti-implantation agent, known as dinordrin(4.3,R=H).
The prim ary sequence o f the progestrone receptor has been 
established as a result o f cloning and the coding o f  the cDNA which is 
responsible for its biosynthesis. The progestrone receptor is a protein 
o f  933 amino acid residues and a molecular weight o f  about 100 000 
Daltons, which is far beyond the scope o f current methodologies for 
calculating 3D structures.
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When the 3D structure o f the biological receptor is unknown, it is still 
possible to develop useful maps o f important stereochemical and polar 
features o f the active site region. This can be done by studying 
receptor interactions with a number o f substrates and using the 
results to gauge the shape, size and character o f  the spaces in to which 
it binds. This form o f blind mapping has been very  successful in 
building up pictures o f receptor regions for many kinds o f drugs: the 
morphine receptors in the nervous system are a good example.
In the present work, an attempt has been made to use the information 
available from published studies o f antiprogestins in order to design a 
novel structure which it is hoped will show im proved receptor 
binding.
An important element o f the reasoning behind the approach adopted 
is that individual structural features built in to a steroid framework 
w ill have additive and / or synergistic effects when combined 
together.
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5.2 TARGET DESIGN
In the present work, the following structural elements have been 
selected as being important to the goal o f developing a new, potent, 
orally-active anti-progestin:
1. From the very large body o f work on both progestins and anti- 
p rogestins, it is assumed that 17 c< -a lkynyl-m -hydroxy
functionality is desirable for good oral potency.
2. A ll the powerful anti-progestins so far identified have had an aiyl 
substituent located either at 118> or on the 18-methyl group. It is 
evident that there must be a pocket o f substantial size located in the 
receptor above the C ring o f the steroid, into which the aiyl group can 
fit. It is therefore desirable that any new anti-progestin should retain 
the presence o f an aryl ( or similar ) function projecting into this 
sector o f space.
3. When looking for additional structural features to supplement 
those already incorporated in the RU and ZK compounds, attention was 
drawn to the A-nor steroids reviewed in Chapter 4. Amongst these 
compounds, anordrin in particular is striking as the only steroid other 
than RU 38486 which has been extensively studied and clinically used 
on a large scale as an anti-implantation agent. Although the clinical 
mechanism o f the action o f anordrin remains in some doubt, there is 
clear evidence for its anti-hormonal properties.
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It was therefore decided that the ring A  pattern o f anordrin should be 
incorporated into the new design: namely, an A-nor ring with a 2 (X
-alkynyl-2K-hydroxy substitution pattern. Combining these three 
types o f  structural elements, it was decided to synthesise a series o f 
A-nor-androstanes having ll&-aryl,2 <X ,17 o< -dialkynyl-2£, m -d io l
substituents (5.1) for investigation o f their anti-progestin properties.
5.3 PROPOSED W ORK
The A-nor structure and ll-[4-(dimethylamino)-phenyl] group both 
independently confer anti-implantation character on the steroid 
nucleus. There is ample precedent to show that the biological effects 
o f  separate functional groups in steroids are often additive (eg. the 
currently used oral contraceptives and anti-inflammatory steroids 
were developed by combining favourable substituents).
It is therefore hoped that by combining the A-nor and 11-aryl 
function a powerful new anti-implantation agent will be obtained
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The strategy involves the synthesis o f an 11-aryl A-nor diketone (5.2) 
to which various nucleophiles can be added at the carbonyl groups.
Initially, the steroid(5.2,R=H) will be prepared, because this should be 
easier to prepare in the absence o f a substituent on the phenyl group. 
By aromatic substitution reactions, a wide variety o f  substituents, 
including NMe2 , can be introduced to give a large series o f 
compounds for testing.
In our own work, a ring contraction method was first examined using 
the cheap and convenient model compound 11-Ketoprogesterone . An 
Italian group has reported^  that this steroidal enone undergoes ring 
contraction using thallium nitrate to give the A-norester (5.4) in 65% 
yield.
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Fig. 5.1
M y colleague, Charles Thomas86, was able to repeat the reaction, 
obtaining the A-nor ester (S.4) but only in 25% yield. The structure 
and purity o f this compound (5.4) were confirmed by analytical and
spectroscopic data. Unfortunately, the reported literature yield  was 
not reproduced.
(5 .5 ) (5.6)
Fig. 5.2
Thomas also examined cortisone acetate (5.5) as a model compound, to 
afford a 45% yield o f the ring contraction product (5.6). The reported 
yield  in the literature87 was 66%. Thomas also carried out the ring 
contraction o f ll-ketoprogesterone(5.7) on a 5g scale, obtaining a 
yield o f 50% o f the diketo ester(5.8).
Thomas carried forward the synthesis from the ring-contracted ester 
(5.8) (Fig 5.3). He was able to obtain a few  milligrams o f the 11- 
phenyl A-nordiketone (5.20) (Fig 5.4).
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Fig. 5.3
The overall objectives o f my work were therefore:
1) to carry out the reaction sequence on a much larger scale, in order 
to obtain large quantities o f the 11-phenyl steroidal enediones (5.18).
2) to investigate methods for the selective reduction o f the double 
bond in (5.18b) (Fig 5.4) in order to obtain the requiredllfc-phenyl 
substitution.
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Fig. 5.4
3) to convert this interm ediatellfi-phenyl diketone into a series o f 
substituted analogues for biological testing (Fig 5.5).
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Fig. 5.5
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CHAPTER 6
Synthetic approaches to 11 fi-arvl-A-nor-androstanes 
6.1 Introduction
The method developed by C.Thomas86in this laboratory was repeated 
on a larger scale, carrying out the ring contraction o f 11- 
ketoprogesterone, using thallium nitrate in a mixture o f trimethyl- 
orthoformate and methanol to give the A-norester (5.8).
This appeared to be a satisfactory method for the introduction o f the 
A-nor-structure. For this reason, it was necessary to scale up this 
reaction even further to make a large amount o f the ring contraction 
steroid (5.20) as an intermediate for the synthesis o f the target 
compound.
6.2 Results and Discussion
The ring contraction reaction on 11-ketoprogesterone (5 .7 ) was 
successfully carried out on a large scale The purity and structure o f 
the 11-keto A-norester (5.8) was confirmed by analytical (TLC) and 
spectroscopic (IR, NMR, MS) data. The XH NMR spectrum o f the 
reaction product (5.8) showed a broad 1H singlet at 5.10 ppm and a 
3H singlet at 3.55 ppm (CO2 Me). Also there were bands at 0,57 (CHd)
ppm  and 1.10 (CH3)ppm. A  singlet at 2.11 ppm was attributed to the 
CH3 next to the carbonyl groupSS. additlon> the spectrum
showed a saturated ester atl724 cm '1 . The mass spectrum o f the 
reaction product showed a peak at m/z 358 corresponding to the 
required molecular ion.
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The mechanism o f the ring contraction reaction is shown in Fig 6.1.
Fig. 6.1
In the next step, compound (5.8) was hydrogenated with palladium on 
activated charcoal in absolute ethanol and acetic acid ( 2:1) fo r  two 
days, a fford ing compound (5.9) in good y ield  (85% ). Catalytic 
hydrogenation o f a steroidal 4-ene norm ally proceeds from  the o', 
-face, due to the steric effect o f the ft-methyl groups. Therefore, the 
A-nor-3-ene (5.8) would be expected to give the trans ring junction. 
The structure o f compound (5.9a) was supported by its 1H NMR and 
mass spectra. However, the NMR spectrum o f the hydrogenation
93
product was difficult to analyze in the region o f the H-5 proton due to 
the close proxim ity o f various signals. The mass spectrum o f the 
reaction product showed a molecular ion peak at m/z 360.
Considerable effort was required to establish conditions suitable for 
the Baeyer-Villiger oxidation o f compound (5.9) to the acetate (5.10). 
A  va rie ty  o f procedures em ploying perbenzoic acid o r  m- 
chloroperbenzoic acid, with and without acid catalysts, were examined 
without success. In general, either unchanged starting material or 
com plex mixtures o f products were isolated. Finally, it was found 
that treatm ent o f com pound (5 .9 ) w ith fresh ly  prepared  
peroxytrifluoroacetic acid88-89 in methylene chloride containing a 
slurry o f sodium phosphate as a buffering agent, gave the acetate 
(5.10) in 80% yield.
(5.8) (5 .9)
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oThe identity o f compound (5.10) was confirm ed by its lH  NMR 
spectrum, which showed a new signal at 4.68 ppm due to the 17-H o f 
the 17 acetate.
The mechanism o f the Baeyer-Viliiger reaction has been discussed in 
the literature90.91 and the reaction proceeds through decomposition 
o f the peroxytrifluoroacetic acid-ketone adduct (5.11) (Fig6.2), which 
by loss o f the trifluoroacetate anion and the concerted migration o f an 
a lky l group yields the ester (5 .10 ). The effectiveness o f 
peroxytrifluoroacetic acid in this reaction is due to the facile 
heterolysis o f the oxygen-oxygen bond induced by the h igh ly 
electronegative trifluoroacetate substitutent.
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Fig.6.2
It  has been established that structural features in the migrating group 
which are best able to accommodate a positive charge facilitate the 
rearrangement. This is due to the build up o f positive charge on the 
peroxy oxygen in the transition state, as the leaving group departs, 
the relative ease o f electron release favouring alkyl m igration in  the 
order 3 >2 >1 . Therefore on oxidation o f compound (5 .9 ), the 
steroidal (secondary) group is the one that migrates, giving an acetate 
ester rather than methyl ester.
The treatm ent o f the 11-ketodiester (5 .10) with excess phenyl 
lithium92 gave a mixture o f compounds (5.12) and (5.13) in a ratio o f 
about 5:6, which were separated by preparative T.LC. The structures 
were assigned on the basis o f their spectroscopic data. Although in 
the mass spectra o f both compounds their molecular ions were not 
present, in both cases, M+- H2O ions were observed. Structure (5.12)
was further confirmed by its 13C NMR spectrum, showing a signal at 
210 ppm due to the carbon o f the C=0 group.
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When the reaction was repeated and the temperature was increased 
from  -78 to 50 °C after the addition o f compound (5.10) and also using 
100% excess Phli, there was no change in yield o f compounds (5.12) 
and (5.13). When pure compound (5.13) was further treated with 
m ore PhLi at -78 °C, a mixture o f compounds (5.13) and (5.12) was 
obtained. When organolithium reagents react w ith a carbonyl 
compound, there exists a competition between addition, reduction and 
enolization, and at -78 °C reduction and enolization are minimized. 
But in  this case the only possible competition would be between 
add ition  and enolization simply because o f the nature o f the 
organolithium  used, i.e. PhLi, a 6 -hydrogen is required in the 
organolithium for reduction to take place.
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Oxidation o f compound (5.13) using dipyridinium dichromate93»94 
gave compound (5.14) in good yield (4.2g, 84%). The infrared 
spectrum o f compound (5.14) showed the expected band atl730 cm ’ 1 
due to the carbonyl group at 017.
The most suitable method for dehydration95 o f secondary and 
tertiary alcohols was found to be the treatment o f compound (5.14) 
w ith freshly prepared CuS04/Si02 in dried cyclohexane under reflux 
which gave two isomeric compounds, (5.15) and (5.16), which were 
separated by preparative TLC. The lH  NMR spectra o f the two isomers 
confirm ed their structures. A singlet signal appeared at 6.0 ppm in 
the *H NMR spectrum o f compound (5.16) but was not present in the 
111 NMR spectrum o f compound (5.15).
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+It was observed that when the dehydration reaction m ixture was 
refluxed gently, compounds (5.16) and (5.15) were obtained in a ratio 
o f 6:1. However, when the reaction mixture was refluxed vigorously, 
the ratio obtained was 1:6.
These results can be explained by kinetic preference fo r abstraction 
o f  the H-12 rather than H-9 . The thermodynamic isomer preferred 
is compound (5.15) as it is more stable.
O zonolysis96 was found to be suitable for the oxidative cleavage o f 
the diphenylmethylene side chain in compounds (5.15) and (5.16). 
Ozone was passed into separate solutions o f compounds (5.15) and 
(5 .16 ) in methylene chloride and after work-up with zinc dust and
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glacial acetic acid, the products (5.17) and (5.18) respectively,were 
isolated by preparative TLC.
The structural assignments o f the isolated compounds (S .17) and 
(5 .18 ) were made on the basis o f their spectral data (IR, 1h  NMR, MS). 
The IR spectra o f compounds (5.17) and (5.18) each showed a strong 
band at 1740 crn 'l due to the two carbonyl groups at positions C-2 
and C-17. Their mass spectra both showed a molecular ion peak at 
m/z 348. The lH  NMR spectra o f both compounds were almost the 
same but the 1h  NMR spectrum o f compound (5 .18 ) showed an 
additional doublet signal at 6.0 ppm due to the olefinic proton at C-12 
A lso, in  the %  NMR spectra o f both compounds there was a m ultiplet 
signal at 7.16 ppm which integrated for 5H's. This evidence indicates
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the loss o f two phenyl groups which is in agreement with the expected 
results.
Up to this point the stereochemistry o f the 5-H in the series o f 
compounds (5.9-5.17) had been tentatively assumed to be 5«on the 
basis that steroidal hydrogenation usually occurs from the underside. 
The complexity o f the 400 MHZ *H NMR spectra in early members o f 
this series had made detailed analysis o f the 5-H signal difficult. 
However, the introduction o f the carbonyl group in the A-nor ring 
and the effect o f a double bond in the C- ring appeared to make the 
product (5.18) a suitable compound in which to explore this point 
further and detailed *H NMR investigations were carried out.
In  the work by my colleague Charles Thomas, two distinct 
approaches were used in the examination o f the C-5 stereochemistry 
in  a steroid such as (5.18). The first was the use o f the Karplus 
equation to correlate the observed coupling constants w ith the 
dihedral angles between 5-H and the nearby protons which are 3R, 
3tf, 66 and 6 * .
However, because o f the complexity o f the 400 MHZ 1h  NMR and 2D 
COSY spectra, the only interaction that could be clearly seen was that 
between the 3-H and 5-H protons. A nice doublet o f doublets o f 
doublets (ddd) was observed for 3R and 3or protons respectively due 
to  interaction with 5-H and the two protons on C -l as a result o f 
coupling through the C-2 carbonyl from both 1h  NMR and the 2D 
COSY spectra. Thomas observed J 3R -5 *  J 3«-5 «9  Hz. These values 
indicated dihedral angles for J 3R -5 *  30-45° and J 34-5 «  160- 
170°.
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However, examination o f models showed that both 5#and 58 isomers 
(5.18a) and (5.18b) could adopt conformations consistent with these 
angles and consequently no conclusive decision could be reached 
from  this approach.
The second method examined was the use o f the technique o f nuclear 
Overhauser enhancement difference spectroscopy (nOeds)86. When 
two protons are in close proximity to one another in a molecule and 
their spins are contributing to one another's NMR relaxation, double 
irradiation o f one proton causes an increase in signal intensity for the 
other. This nuclear Overhauser enhancement can reach as much as 
50% o f the original signal size, but is often much smaller (due to 
factors o f distance and the relaxation contributions o f all other 
adjacent protons). The power o f the nOeds technique, in which the 
norm al spectrum is subtracted from  the enhanced one on double 
irrad ia tion , lies in the ab ility  to sensitively detect small 
enhancements.
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T ab le .& l 1H_MMfLand nOeds^-esults for fg,2oh) in co n *
A  se i gri­
mant
• S(PPM) No. of 
hydrogen
s Mu 11 1p 1Iclty • NOeS T0
1? = 1.28 1 = dd = m , 19^,3/
3fi s 2.4 = 1 = ddd = 5,3*C, Ip
3 X s 1.96 r 1 = ddd s 6*Ç,5
7 K s 1.85 s 1 = multiplet s 7ytf, 14*, 9*,8^, 6oc
14*t 1.75 s 1 — multiplet m» 9«C, 16* ,8,12,7*
18/f s 1.09 s 3 s S s 12,15/, 160?, 190?
19p = 0.8 s 3 s s s 5.60, 1/8,87
— Ph(2 ', 6 * ) , 18/6
9K s 2.6 = 1 r multiplet s 1K,14IC,7*C
— P h ( 2 ’,6*)
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For the two possible structures (5.18a) and (5.18b), the most obvious 
feature to search for is the presence o f nOe's to and from  the 19-Me 
group. In particular, nOe's between this group and C5-H would be 
indicative o f cis stereochemistry (5.18b).
W hen a series o f nOe experiments were run on compound (5.18b) in 
CDCI3 (table 6.1), a clear nOe was observed86 at H-5 on irradiation 
o f  19-Me, consistent with cis stereochemistry (5.18b).
There were also nOe's from 19-Me to H-18, H-68, H-88 and 18-Me 
which were consistent with the conformation (X). Interestingly, when 
the nOe difference spectra were collected on (5.18) in deuterated 
toluene, no nOe could be observed for 19-Me to H-68. Models suggest 
that the alternative, 8-ring boat conformation (Y ) is accessible fo r the 
cis-fused isomer and this could be more strongly favoured in some 
solvents.
In  summary, the nOeds evidence clearly indicates that compound 
(5 .18 ) has 5-8 stereochemistry (5.18b) with a cis fusion o f the A  and 
B rings.
Since none o f the processes involved in the conversion o f the diketo 
ester (5 .8 ) into compound (5.18b) could possibly have resulted in 
inversion  o f the stereochemistry at C-5, it follows that all the series 
( 5 .8) to (5.18) have this same stereochemistry i.e. (5.8b) to (5 .1 8 b ).
T h e formation o f the cis-fused diketo ester (5.9b) from  the 3-ene (5.7) 
m ay have two possible explanations. Firstly, it is known that when
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hydrogenation is carried out in an acidic medium, as in the present 
case, it is possible for trans-hydrogenation to occur by the addition of 
one hydrogen atom from  the catalyst surface and capture o f a proton 
from  the opposite face o f the olefin.
However, in the present case an alternative explanation seems 
reasonable. Due to the ring contraction to an A-nor steroid and the 
presence o f the methoxy carbonyl group at 0 2 , the steric effects o f 
the 19-Me are counterbalanced by those o f the ester group.
Models suggest that the conformation Fig (6.3) o f the substrate (5.7) 
may make approach to the catalyst surface more favourable from  the 
ft-face. On the basis o f the evidence for the 5ft configuration in the 
diketo ester (5.9b), it was concluded that the structures o f all 
compounds (5.9M5.18) must be assigned to the 5ft series.
Since the original intention o f this project had been to synthesise a 
5 -A-nor steroid combining structural elements from  anordin and
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RU 38486, the unexpected acquisition o f the 5R series required re- 
evaluation. The model suggested that this inversion o f configuration 
at 0 5  would not dramatically alter the overall shape o f the final 
steroid or its ability to bind to the progesterone receptor.
It was also encouraging that the inversion o f stereochemistry at the 
C/D ring junction in ZK 98299 did not lead to loss o f antiprogestational 
activity. It was therefore decided to continue the previously planned 
synthesis, but with the 5£ series.
Following the literature97method for the ketalization o f progesterone, 
ll-phenyl-A-nor-5^androst-ll-en-2,17-dione (5.18b) was refluxed 
for 3 hours with ethylene glycol, p-toluene sulphonic acid as a catalyst 
and d ry  benzene in a Dean and Stark apparatus, to a fford  2,2- 
ethylenedioxy-11 -phenyl-17,17-ethylenedioxy-5 -norandrostane 
(5.19), which was isolated and identified by its spectra. The 111 NMR 
spectrum indicated the appearance o f a multiplet between 3.9-3.65 
ppm corresponding to 8 hydrogen atoms in two ketal functionalities. 
Also present was a 1H singlet at 6.06 ppm corresponding to the C-12 
H. The IR spectrum o f the compound did not show a band at 1740 
cm "l, confirming the loss o f two carbonyl groups at positions C-2 and 
C-17. Its mass spectrum showed a molecular ion peak at m/z 436.
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o o  o
H ydroboration  o f com pound (5 .19b ) using diborane98 in 
tetrahydrofuran gave compound (5.20). The structure o f the 
compound was confirmed by its NMR spectrum which showed an 
absence o f the singlet olefin signal that was present in the lH  NMR 
spectrum o f compound (5.19b).
It was also observed that the lH  NMR spectrum o f compound (5.20) 
showed the absence o f the ketal signals that were present in the *11 
spectrum o f compound (5.19b) at 3.9-3.65 ppm.
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A number o f attempts were made to nitrate compound (5.20b) with 
concentrated nitric acid and sulphuric acid in acetic acid^ lO O .
In none o f these attempts were we able to isolate the desired product 
(5.21b) or any other side product from the reaction mixture.
The strategy reported by Kirk and Petrow101 involved the action o f 
organom etallic reagents on an 11-keto steroid fo llow ed  by 
dehydration and a catalytic hydrogenation procedure. This 
m ethodology was further utilised in the synthesis o f 11R -ethyl 
estrone and H R  -ethyl-n-propyl and-n-butyl estrones101. In the 
hope o f achieving a similar result, the keto diester (5.10) was treated 
with an excess o f 4-(N,N-dimethyl) phenyl magnesium bromide, to try 
to produce the triol (6.1). Unfortunately we were not able to isolate 
the desired product.
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6.3 CONCLUSION AND SUGGESTIONS FOR FURTHER WORK
The work described in this chapter has led to a successful route being 
established for the synthesis o f 11-phenyl-A-nor-5R-androstene-2, 
17-diones having a double bond in the C-ring. The double bond needs 
to be reduced to furnish the 1 1R -phenyl-diketone, which is required 
fo r the synthesis o f novel compounds for testing as anti-hormanal 
agents.
Reduction o f the C-ring olefin was achieved by using diborane in 
tetrahydrofuran. Alternatively, the two carbonyl groups could be 
protected as ketals.
Once the H R  -phenyl diketone ( 5.20 ) is available, it is anticipated 
that it can be converted into the final products as shown in Fig 5.5.
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CHAPTER 7
E X P E R IM E N T A L
A ll chemicals and solvents were purchased from  Aldrich, Fluka, 
Jansens and Sigma. The solvents were o f SLR grade and dried where 
necessary according to the procedures cited in the literature1021 
M elting points were determ ined on a Gallenkamp M elting point 
Apparatus and are uncorrected. Infrared spectroscopy was performed 
on samples in the individual methods on a Perkin Elmer instrument 
(FT-IR 1720X spectrometer) and recorded as wavenumber (cm-1). 
NMR and 1^C NMR were perform ed on a Bruker AC 250 MHz or a 
Bruker AC 400 MHz spectrometer in CDCI3 solutions. Chemical shifts 
are quoted in ppm( S ) and TMS was used as an internal standard. Low 
resolution EI-MS,CIMS(NH4+) and FAB-MS were obtained on a Kratos 
MS-80 mass spectrometer. High resolution EI-MS and CI-MS(NH4+) 
were obtained from  the SERC Mass Spectrometry Service Centre, 
University College o f Swansea. Column chromatography was carried 
out using Kieselgel 60 (particle size 40-63>*m). Organic solvents were 
removed under reduced pressure on a Buchi rotary evaporator.
1 1 1
Srx-METHOX YC ARBONYL-A-NORPREGN-3-ENE-11. 20-DIQNE
(large scale preparation) (5.8) .
Thallium (III) nitrate (25g, 49 mmole) was dissolved in a mixture o f 
trim ethyl orthoformate (206.7ml) and methanol (159m l), and the 
resulting solution left stirring at 0 °C for 30 minutes. A cold (0  °C) 
solution o f 11-ketoprogesterone (5.7) (15.6g, 38.2mmole) in a mixture 
o f trimethyl orthoformate (312.7ml) and MeOH (238.2ml) was quickly 
added. A fter 30 mins, the reaction solution was neutralised with 
saturated aqueous sodium carbonate, then filtered and extracted with 
diethyl ether. The ether was then evaporated and a white o ily  solid 
was form ed. The product was purified  using silica colum n 
chromatography. On elution with a mixture o f hexane-ether (20:80), 
pure 2«(-m ethoxycarbonyl-A-norpregn-3-ene-ll,20-dione (5.8) was
afforded (lO g, 64%); M.P. 99-102 °C. Analytical TLC showed Rf=0.673. 
lHNM R(CDCl3) i :  5.06 ( lH,s),3.55 (3H,s), 2.11 (3H,s), 1.10 (3H,s) and
0.57 (3H,s). 0 max (CHCI3) cm-1 1700-1727, 1521: EI-MS; m/z: 
358.4709 (M +,15.89%, C21H260 5 requires 358.4778), 356, 345, 329,
328, 313, 301, 300, 285, 257, 244, 240, 219, 206,193,175, 165, 161, 
159,151,135,133,131,123,121,119,109,108,107,105, 95, 94, 93, 
91, 85, 81, 80, 79, 77, 71, 69, 67, 59,55 (100%), 53.
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2a-M E TH O X Y  C AR B O NYL-A -NO R -56-PR EG N AN E -11.20-DIQNE 
(5.9b)«
A  solution o f compound (5 .8) (5.0g, 13.9 m m ol) was added to 
palladium on activated charcoal (1.3g, 10%) suspended in glacial acetic 
acid (150 m l) and ethanol (300 m l) and the mixture was stirred 
magnetically under hydrogen. The hydrogenation took place over a 
period o f two days, and after this the mixture was filtered  and 
evaporated giving a yellow solid (5.9b), (4.3g 85% yield ), MP 124-128 
•c, XH NMR (CDC13)i: 3.62 (3H,s ), 2.10 (3H,s),1.22 (3H,s) and 0.S5 
(3H,s); J  max(CHCl3) cm "l 1700-1728; EI-MS: m/z :360.4735 (M +, 
137.5%; C22H32O4 requires 360.4715), 345, 285, 258, 219, 206,133,
107, 95, 93, 91, 85, 81 (100%), 79, 77.
2a-M E TH O X YC A R B Q N YL-A -N O R .56 -A N PR O S TA N .176 -O L .ll.O N E  
A C E T A T E  (5.10b).
A  solution o f peroxytrifluoroacetic acid was prepared by adding 60% 
hydrogen peroxide (3.6 ml, 75.6mmol) dropwise to a well stirred, cold 
solu tion  o f triflu roacetic anhydride (16m l, 207.7m m ol) in 
dichloromethane (22.4 m l). The mixture was then allowed to warm 
up to room  temperature with stirring and then cooled in an ice bath 
fo r 3 mins. This solution was added over 15 mins to a well stirred 
m ixture o f disodium hydrogen phosphate (26g, 183m m ol) and 
compound (5.9b) (lg , 2.8mmol) in methylene chloride (100 m l).
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After addition was completed, the mixture was heated under reflux 
fo r 4 hours. The product was then filtered  and washed with 
methylene chloride. The combined filtrates were washed with 300 ml 
o f 10% sodium carbonate and dried over magnesium sulphate and 
then filtered. The filtrate was collected and evaporated. The crude
product was then dried, and obtained as a pale yellow  oil. Compound 
(5.10b), 0.8g (80%). lH  NMR (CDC13)£ : 4.68 (lH ,t), 3.65 (3H,s), 1.93
(3H,s), 1.14 (3H,s) and 0.66 (3H,s); >? max (CHCI3) cm-*: 1700-1730; 
El: MS m/z: 376.2446 (M +, 5.67%; C22H32O5 requires 376.2441), 361,
360, 329, 302, 301, 284, 283, 235, 222, 209,149, 135,133, 121, 119, 
109, 107, 105, 97, 95, 93, 91, 84, 82, 81, 80, 79, 77, 69, 67, 59, 57, 55 
(100%), 55,53.
2 (1  '-H Y D R O X Y -l M  '■D IP H E N Y LM E T H Y D -l 1 a -H Y D R O X Y . 11B 
P H E N Y L  A-NOR-5B-AND RO STAN-17B-OL(5.13b l: 2 -il'-H Y D R O X Y .
1 '.1 '- D IPH E N YLM E TH YL)-A -N O R -5R -AN D R O STA N -176-01,-11 - 
ONE.(5.12b).
A  cold solution o f compound (5.10b) (l.Og, 2.6 mmol) in dry ether (10 
m l) was added by syringe into a stirred solution o f 2M phenyl lithium 
(100 ml, 200mmol) in dry hexane-ether m ixture (90:10) under 
nitrogen at -78 °C. A fter the addition was com plete the reaction 
m ixture was allowed to warm up to room  temperature and then 
stirred fo r one hour. The reaction mixture was cooled in an ice-bath 
and a cold saturated ammonium chloride solution was added dropwise
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with stirring. The ether layer was separated and the aqueous layer 
extracted with ether. The combined ether extracts were dried over 
magnesium sulphate and evaporated to yield a brown oil. The crude 
product was purified by preparative TLC using ether-hexane (8:2) as a 
solvent to give compounds (5.12b) (320mg, 23.55%) and (5.13b),
(350m g, 29.90%) respectively. Compound (5 .13b): white solid, 
M.P.244-246 °C l E  NMR (CDC13) i : 1.02 (3H,s), 1.3 (3H,s), 2.74 ( lH,m),
3.32 (lH,t), 6.78 (lSH^/imaxiCHC^)
cm '13393: EI-MS : m/z 518.3161 (M+-H20, 10.28% C37H4202
requires 518.3197). Compound (5.12b) white solid M.P.123-129 °C; 1H 
NMR (CDCl3)i700, 1597: EI-MS : m/z 440.2973 (M +-H20, 8.92%,
C31H33O3 requires 440.2959). The reaction was then repeated twice 
on a large scale and a total o f 8 g o f compound (5.13b) accumulated.
2-Q H Y D R O X Y -IM  -D IP H E N Y LM E T H Y L )-1 la -H Y D R O X Y -116- 
PH ENYL-A-NO R-5B- A N P R O S T A N -17-ONE (S A 4 b ).
Pyridinium dichromate (20.58g, 39.4mmol) was added to a solution o f 
compound (5.13b), (5g, 10 mmol) in dichlorom ethane at room  
tem perature. The reaction mixture was stirred fo r four hours. 
Dilution o f the reaction mixture with ether, removal o f the precipitate 
and concentration o f the filtrate under reduced pressure gave the 
crude compound (5.14b),(4.2g, 84%). Some o f the crude product 
(lOOmg) was purified by preparative TLC using (2:8v/v) hexane-ether 
as solvent, M.P.244-251 *C. iH N M R (C D C lj) :1.21 (3H,s), 1.38 (3H,s),
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as solvent, M.P.244-251 °C. lH  NMR (CDC13)/:1.21 (3H,s), 1.38 (3H,s), 
2.87 (lH ,m ), 7.26(15H,m);\?max (CHCI3) cm"1 1730 (s), 1600; EI-MS, 
m/z 534.2563 (M+, 1.2%, C37H42O3 requires 534.2549).
P R E P A R A T IO N  O F CUSO^/SiCH SO LID  PH ASE  D E H Y D R A T IN G  
R E A G E N T.
The reagent was prepared by mixing chromatographic^5 silica gel 
(230-400 mesh) (25.0g, 420 mmole) with copper (II) sulphate 
pentahydrate (16.60g, 70 mmole) in water (20 m l). The water was 
evaporated under reduced pressure and the solid dried for two hours 
at over 200°C. At this stage there was no further water condensation 
in a trap cooled with liquid nitrogen. The product was then allowed to 
cool slowly over night in a vacuum desiccator over phosphorus penta 
oxide.
2 - ( l 1 *-D IPH E N YLM E TH YLE N E )-l 1 -PH E N YL-A -N O R-S  B - 
AND RO ST-1 l-EN-17-O NE,(5.16b)-2-(lM  '•D IPH ENYLM ETH YLENF/U  
11 -PH E N YL- A-NOR-5B-ANDROST-9-EN-17-ONE (5.15h).
To a solution o f compound (5.14b),(50mg, 0.095 mmol) in carbon 
tetrachloride (5m l) was added copper (II) sulphate on silica gel 
(509mg, 3.32 mmol). The resulting reaction mixture was refluxed at a 
tem perature between 90-95 °C for 75 mins. The reaction was 
monitored by analytical TLC, and after the completion o f the reaction, 
the crude products were isolated from the solid by filtration.
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The filtrate was evaporated to dryness under reduced pressure and 
the residue was purified by preparative T.L.C. using dichloromethane 
as solvent, to afford two olefinic compounds (5.16b), (29mg, 58%) and 
(5.15b), (9 mg, 18%) respectively. Compound (5.16b) white solid, 
M.P.113-H8 °C; ! h  NMR (CDCI3) £ : 0.94 (3H,s), 1.02 (3H,s), 6.05 (lH ,s),
7.16 (15H,m); '¿max (CHCI3) cm’ 1 :1739, EI-MS: m/z 498.2938 (M + 
,11.35%; C37H3gO requires 498.2922), compound (5.15b): white solid, 
M.P. 124-128 °C; ! h  NMR (CDCI3) * :  1.01 (3H,s), 1.23 (3H,s), 7.12 
(15H,m);>?max (CHC13) cm’ 1 :1735 EI-MS: m/z 498.2926 (M +,21.12%; 
C37 HggO requires 498.2939.
11 -PHENYL-A-NOR-5&-ANDROST-11-ENE-2.17-D IONE (5.18b).
A  solution o f com pound(5.16b), (300m g, 0.62m m ol) in dry 
dichloromethane (13.5ml) and dry pyridine (0.06ml) was ozonized for 
45 minutes using a stream o f ozone-oxygen with stirring at -78°C.
By this time the colour o f the reaction mixture had changed from  
deep orange to yellow. To this pale yellow reaction solution, zinc dust 
(350mg, 5.35mmol) and glacial acetic acid (1.52ml) were added and 
stirring was continued for 15 mins at 0°C and finally, for 5 mins at 
35°C. The bright yellow  solution was rem oved from  the zinc by 
filtration and was washed with two 5ml portions o f water. It was 
then cooled by the addition o f ice and washed with 20ml and 10ml o f 
cold 10% sodium carbonate, 10ml o f cold 10% sodium hydroxide and 
four 50ml portions o f cold water, all aqueous washes being back- 
washed with 50ml o f methylene chloride.
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The fine white precipitates which formed at the interfaces during the 
extraction were separated with the aqueous phases and discarded. 
The combined methylene chloride solutions were dried over sodium 
sulphate, filtered and concentrated to dryness at 40°C under reduced 
pressure to produce a crude oily yellow compound. This was purified
by preparative T.L.C. using ether-hexane (80:20 v/v) to give 
compound (5.18b), (44.5mg, 15%) M.P. 191-193°C: *11 NMR (CDC13)$
:0.96 (3H,s),1.08 (3H,s), 6.03 (lH ,d ), 7.16 (5H ,m );^m ax (CHC13)
cm 1:1740; EI-MS: m/z 348.2054 (M  + , 22%, C24H2802 requires
348.2125).
In the same experim ental conditions, compound (5.15b) gave 
compound (5.17b) (50.2mg, 17%). Compound (5.17b): M.P.142-148°C; 
lH - NMR(CDCl3)i:1.02(3H,s),1.28(3H,s), 7.15(5H,m):')max(CHCl3) cm“l: 
1735; EI-MS: m/z 348.2042(M+, 100%, C24H28O2 requires 348.2129).
;17.17-BIS iE T H Y LE N E  D IO X Y U  1-PH ENYL-A-NO R-5 -B 
AN PRO ST-11-EN E (5.19b).
A  mixture o f compound (5.18b), ( 1.0 g 2.9 mmol ), ethylene glycol 
(5m l), p-toluenesulphonic acid ( 0.025 g ), and benzene ( 20 m l) was 
heated under reflux for 48 hours in a 1-L round bottom flask equipped 
with a Dean -Stark trap. Saturated sodium bicarbonate solution ( 2.5 ml 
) was added to the cooled mixture and the benzene layer was separated, 
washed with water ( 2 x 5  m l) dried (Na2SC>4), and concentrated to
dryness under reduced pressure. Recrystallization from  ethanol gave
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pure compound (5.19b), (0.7 g, 70% yield ): mp 185-187.5 “C.^H- 
NMR(CDC13) S :0.94 ( 3H, s), 1.15 ( 3H, s ), 6.06 ( 1H, d ), 7.18 (5H, m ), 
3.65-3.98 ( 8H, m - OCH2CH2O -) ;^max (CHCI3 ) cm-1 1438,1370, 
1313, 1102; El - MS: m/z 436.2185 ( M+ , 35%, C28 H36 O4 requires 
436.2176).
11-PH E N YL-A -N O R -5 R-ANPROST-2.17- D IO NE (5.20b).
In a three-neck flask was placed the compound (5.19b), ( 0.1 g, 0.23 
m m o l ) in 0.1 ml o f tetrahydrofuran. The flask was immersed in an 
ice-bath and a standard solution o f diborane in tetrahydrofuran, 0.1 
ml, was added dropwise by means o f a syringe to the compound 
(5.19b) in tetrahydrofuran. The reaction mixture was perm itted to 
remain for 2 hours at 0-5°C.
The residual diborane was destroyed with ethylene glycol. A fter 
addition o f 0.3 ml o f glacial acetic acid, the flask was perm itted to 
remain overnight at room temperature. The reaction mixture was 
poured in to ice-water. The upper layer was separated, washed with 
sodium hydroxide solution and then with a saturated sodium chloride 
solution, dried and concentrated to dryness under reduced pressure. 
The crude product ( 0.06g) was purified by preparative TLC using 
100% dichloromethane to give compound (5.20b), ( 0.04 g, 40% y ie ld ). 
1h  NMR (CDCI3 ) £ :  1.02 ( 3H, s ), 1.12( 3H, s ), 7.14 ( 5H, m )tfm ax
(CHCI3 ) cm -li742 H-MS: m/z 350.2245 ( M+, 25% C24 H30 O2 requires 
350.223 ).
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